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ABSTRACT 
Zhengmao Ye: Modulation of Innate Immunity by Nucleotide Binding 
-Biochemical and Functional Characterization of a CATERPILLER/NLR Protein, 
Monarch-1/NLRP12 
(Under the direction of Dr. Jenny P.-Y. Ting) 
 
The recently discovered Nucleotide Binding Domain-Leucine Rich Repeat (NLR) 
gene family is conserved from plants to mammals and several members are associated with 
human autoinflammatory or immunodeficiency disorders.  This family is defined by a 
central nucleotide binding domain that contains the highly conserved Walker A and 
Walker B motifs.  Although the nucleotide binding domain is a defining feature of this 
family, it has not been extensively studied in its purified form.  In this thesis, we show that 
purified Monarch-1/NLRP12, an NLR protein that negatively regulates NF-κB signaling, 
specifically binds ATP and exhibits ATP hydrolysis activity.  Intact Walker A/B motifs are 
required for this activity.  These motifs are also required for Monarch-1 to undergo self-
oligomerization, TLR- or CD40L- activated association with NIK and IRAK-1, 
degradation of NIK, and inhibition of IRAK-1 phosphorylation.  Stable expression of a 
Walker A/B mutant in THP-1 monocytes results in increased production of 
proinflammatory cytokines and chemokines to an extent comparable to cells in which 
Monarch-1 is silenced via shRNA. In addition, the functional role of conserved motifs in 
Monarch-1 NBD domain is examined. The results of this study are consistent with a model 
wherein ATP binding regulates the anti-inflammatory activity of Monarch-1.
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Chapter 1 INTRODUCTON
1.1 The Introduction of NLR protein family 
Vertebrates rely on a robust immune system to combat pathogen invasion. The 
immune response of jawed vertebrate is comprised of two arms: the adaptive and the innate 
immune response. The adaptive immune response is mainly conducted by T and B cells 
that utilize somatically rearranged receptors to specifically recognize antigen. Upon 
activation, T and B cells undergo clonal expansion to achieve effective immune protection. 
In the primary adaptive immune response, the activation, expansion and differentiation of 
T and B cells often require several days, during which the fast acting innate immune 
system exerts its critical role for the eradication or at least the containment of the invading 
pathogen. The innate immune system is mainly mediated by macrophages, mast cells, 
neutrophils, and natural killer cells, which do not possess somatically rearranged receptors. 
Then, how does the innate immune system recognize invading pathogens and distinguish 
them from our own body? It has been predicted by Charles Janeway nearly18 years ago 
that the innate immune system must bear a battery of germline encoded receptors, which 
he termed pathogen-recognition receptors (PRRs),  to specifically detect certain invariant 
pathogen derived products, which he termed pathogen-associated molecular pattern 
(PAMP) (1). In addition, Matzinger also predicted that the invading pathogen could induce 
certain perturbation of normal physiological condition. This perturbation servers as the 
‘danger signal’ that alert the innate immune system (2). 
In 1997, the discovery and characterization of the first mammalian Toll-like 
receptor (TLR): TLR4 (3), significantly advanced our knowledge of the innate immune 
system. Toll-like receptors are germline encoded type I transmembrane glycoproteins that 
specifically detect PAMPs. So far, there are 10 and 11 TLRs identified in humans and mice, 
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respectively. Each TLR recognizes various PAMPs derived from bacteria, viruses, fungi, 
and/or protozoa: TLR4 recognizes lipopolysaccharide (LPS), a major component of Gram 
negative bacteria cell wall; TLR2 heterodimerizes with TLR1 to sense bacterial triacylated 
lipopeptides; TLR2 also forms heterodimer with TLR6 to detect bacteria diacylated 
lipopeptides. Other TLRs can respond to pathogen-derived nucleic acid. TLR3 detects viral 
derived double-stranded RNA (dsRNA); TLR7 and 8 sense viral single-stranded RNA 
(ssRNA) and TLR9 recognizes unmethylated CpG DNA. TLRs also detect pathogen-
derived proteins. TLR5 recognizes bacteria flagellin and murine TLR11 recognizes a 
profillin-like protein from Toxoplasma gondii (4) . In addition to the detection of pathogen 
derived products, TLR2 and TLR4 have been demonstrated to sense fragments of the 
extracellular matrix component hyaluronan, highlighting the role of TLR in recognizing 
self-body derived danger signal (5). 
All TLR contains a C-terminal extracellular leucine-rich repeats (LRR) domain, a 
transmembrane domain, and a cytosolic TIR (Toll/IL-1β Receptor) domain. The LRR 
domain is responsible for the pathogen detection. Upon receiving stimulations from their 
cognate ligands, TLRs transmit the signals via a myriad of intracelluar adaptors including 
MyD88,  MAL (MyD88-adaptor-like,  also know as TIRAP), TRIF (TIR-domain-
containing adaptor protein inducing IFN-β , also known as TICAM1), TRAM (TRIF-
related adaptor molecule, also known as TICAM2) and SARM (armadillo-motif-
containing protein), to activate the nuclear factor-κB (NF-κB), mitogen-activated protein 
Kinase (MAP Kinase), and interferon(IFN) signaling pathways. The activation of those 
pathways results in the secretion of proinflammatory cytokines and chemokines such as 
IL-1β, TNF-α, IL-8, and type I IFNs and the upregulation of costimulatory molecules, 
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which facilitate the activation of the adaptive immune system. The overall effect of TLR 
signaling not only controls the pathogen spreading but also serves as a key bridge between 
the innate and the adaptive immune response. TLRs mainly reside on the cell surface. 
Some TLRs localize in the endosomal compartment. However, many bacteria and all 
viruses are cytosolic pathogen. Thus, it was postulated that there must be cytosolic 
molecules that are able to sense the intracellular PAMPs or danger signals. 
During the search for the MHC class II transactivator (CIITA) homologs in the 
human genome, our group first discovered a novel protein family, which is now thought to 
mainly mediate and regulate intracellular inflammatory response. We christened this 
protein as CATERPILLER (CARD (caspase recruitment domain), transcription enhancer, 
purine binding, pyrin, lots of leucine repeats) gene family (6-8). Subsequently, another 
group identified a similar class of genes called NOD (nucleotide oligomerization domain) 
(9) or NOD-LRR (10), while others reported a subset of  the family called PYPAF (11), 
PAN (12), and NALP (NACHT leucine-rich repeat and PYD containing protein ) (13) 
according to their own specifications. Currently, according to the recommendation of 
human Genome Organization (HUGO), the CATERPLLIER gene family along with other 
similar gene families are unified as NLR (nucleotide-binding domain, leucine-rich repeats 
containing) family. (See table 1 and http://www.genenames.org/genefamily/nacht.html). 
This nomenclature is recommended to be used by the scientific community in the future 
publications. Because this nomenclature has not been formally announced, I will still use 
the most common gene names in this thesis, but use the proposed nomenclature for genes 
that are not well characterized. 
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The NLR proteins are defined by their tripartite domain architecture that contains a  
nucleotide binding-domain (NBD also known as NACHT (NAIP,CIITA ,HER-E ,TP-
1) domain) (14), at the center of the protein. The NBD domain has been implicated to 
mediate self-oligomerization and other regulatory functions. At their C-terminal, most 
NLRs contain LRR domain that are variable in the repeat composition and number. The 
LRR domain has been implicated in mediating autoregulation, protein-protein interaction 
and ligand detection. For example, the LRR of NOD1 and NOD2 are thought to sense 
peptidoglycan, the breakdown product of bacteria cell wall component. The N-terminal 
domain of NLRs varies within the NLR protein and is the basis for the definition of NLR 
subgroups. The largest subgroup (14 members) contains an N-terminal pyrin domain. The 
rest of NLR subfamilies contain a CARD, BIR (baculoviral inhibitory repeat), 
transactivator domain or uncharacterized domains. The N-terminal domain has been 
demonstrated to recruit downstream effector molecules, therefore also known as effector 
domain. 
To date, no crystal structure of a full length NLR protein is reported. Nevertheless, 
the pyrin domains of NALP1 and ASC are elucidated by nuclear magnetic resonance 
(NMR) analysis(15, 16). The crystal structure of NOD1 CARD domain has also been 
depicted recently (17). Pyrin and CARD domains belong to the death domain superfamily, 
hallmarked by the presence of the six-helical bundle fold structure. The pyrin domain from 
NALP1 and ASC both obtain a classical six-helical bundle fold but with a unique H3 helix 
(15, 16). The LRR domain has been proposed to mediate ligand sensing. So far, direct 
evidence demonstrating the binding of the NLR LRR to its cognate ligand is lacking. 
However, the crystal structure of LRR domain of TLR may shed some light on this issue. 
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The crystal structure of the ectodomain of TLR3 displays a horseshoe-shaped array of 
LRRs that is formed by  the interconnected β-strand of each LRR facing the concave side 
and α-helix of each repeats forming a outfacing convex side (18). The binding pocket for 
the dsRNA on TLR3 is postulated to be located at the convex side of LRR. This binding 
activates the homodimerization of TLR3. The exciting breakthrough in understanding the 
role of LRR in PAMP detection was reported by two groups. They showed the crystal 
structure of TLR4 with its cognate ligand LPS (19) and TLR1/2 heterodimer with its 
synthetic ligand Pam3Cys4 (20). Although the overall shapes of LRR domain of TLR4 and 
TLR1/2 heterodimer are generally similar, the ligand binding mechanisms are dramatically 
different. While the TLR1/2 synthetic ligand Pam3Cys4 directly binds to the convex side 
of TLR1/2 LRR domain, the TLR4 agonist LPS binds to the concave side of TLR4 LRR 
indirectly through an intermediate protein MD2. For the first time, these studies not only 
provide us the direct evidence of receptor-ligand binding of TLR but also elucidate the 
potential binding mechanisms. In the light of these findings, the resolution of structure of 
NLR proteins with their interacting partners would be the next breakthrough. 
NLRs are highly conserved through evolution with orthologs found throughout 
vertebrates. In contrast to the evolution of TLR, exhaustive database searches of 
Drosophila and Caenorhabditis elegans genomes do not yield significant hits with typical 
NLR tripartite domain structure. Interestingly, a recent database search in Sea Urchin 
genome yields 203 putative NLRs in contrast with 22 members in humans (21, 22). This 
result indicates that the size of NLR pool might reflect  the different selective pressures 
maintained on each population.  
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NLRs are structurally and functionally related to the plant disease resistant protein 
(R protein) family that confers major anti-microbial response in plants. Plants have a large 
family of R proteins. For example, Arabidopsis has 140 R proteins (23), rice has over 500 
R proteins (24). Structurally similar to NLR protein, plant R proteins contain a tripartite 
domain structure that consists of a C-terminal LRR, a central NBS (Nucleotide binding site) 
domain and an N-terminal domain that contains either a TIR or a coil-coil domain. R 
proteins sense and respond to pathogen-derived molecules that are encoded by pathogen 
avr (avirulence) genes. However, in contrast to certain TLRs, in most cases,  R protein 
mainly respond to the stress or the perturbation that is caused by the intrusion of pathogen-
derived effector on a ‘one-for-one’ fashion, instead of direct recognizing the pathogen-
derived molecules. This theory is called the "Guard Hypothesis" (25). Upon activation by 
their cognate ligands, R proteins elicit swift biological responses that lead to the localized 
cell death and  confinement of pathogen spreading. The R protein mediated protective 
response is often called Hypersensitive Response (HR). Interestingly, two recent reports 
highlight that R protein mediated anti-pathogen response and mammalian NLR mediated 
inflammatory response might share certain common grounds.  To exert its function, plant 
R protein interacts with heat-shock protein 90 (HSP90) and an ubiquitin ligase-associated 
protein SGT1. Similar to plant R protein, Mayor et al reported that many NLRs such as 
cryopyrin interact with SGT1 and HSP90. The interactions between cryopyrin, SGT1 and 
HSP90 are required for cryopyrin mediated inflammasome activation (26). In another 
study, Correia et al demonstrated that NLR protein NOD1 associates with SGT1 and 
HSP90. This interaction is essential for the NOD1 activation (27). Very recently, Arthor et 
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al also demonstrated that Monarch-1 interacts with HSP90 and this interaction is important 
for Monarch-1 induced NF-κB inducing kinase degradation (28). 
The importance of NLR proteins in the regulation of the innate immune response is 
manifested by its association with a variety of inherited immunologic disorders. CIITA is 
the funding member of CATERPILLER family. Mutations in this gene result in the loss or 
reduction of MHC class II expression that causes type II Bare lymphocyte Syndrome 
(BLS); Mutations in CIAS1 gene, which encodes protein cryopyrin, cause a trio of 
autoinflammatory diseases (29): FCAS (familia cold autoinflammatory syndrome), MWS 
(muckle-wells syndrome), and NOMID/CINCA (neonatal onset multisystemic 
autoinflammatory disease/chronic infantile neurological cutaneous and articular syndrome); 
NOD2 mutations are associated with Crohn's disease (30, 31) and Blau syndrome (32).  
Crohn’s disease is one of  two forms of inflammatory bowel disease and Blau syndrome is 
a rare autosomal inflammatory disease characterized by fever, arthritis, uveitis, and 
dermatitis. Moreover, mutations in NAIP gene are thought to be associated with spinal 
muscular atrophy (33), although more recent evidence suggests otherwise. Nonetheless, 
NAIP is important for the recognition of Legionella flagellin (34) . Finally, although not a 
member of the NLR family, the mutations in the gene Pyrin, which shares the pyrin 
domain with NLRP subfamily, are associated with familial Mediterranean fever (FMF) 
(11). 
NLRs display diverse expression patterns. As expected, many NLRs are expressed 
within the innate immune system. For example, human cryopyrin is expressed mainly in 
monocytes/macrophages, although the expression pattern in mouse extends to 
chondrocytes and lymphocytes. Some NLRs are more ubiquitously expressed. Interestingly, 
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NALP5/NALP5/MATER presents an oocyte restricted expression pattern. Mouse Nlrp5 
has been demonstrated to play an important role in embryonic development (35) . 
Furthermore, the maternal mutation of human NLRP7 has been recently linked to 
hydatidiform mole (HM) further implicating that certain NLRs might play important roles 
in the reproduction systems (36). 
1.2 The role of NLR in the control of IL-1β secretion 
IL-1β, also known as the endogenous pyrogen, is a major proinflammatory 
cytokine that mediates host responses to microbial infection and tissue injury. Once 
secreted, it exerts multiple biological activities on host cells bearing its receptor. IL-1β has 
been shown to induce a plethora of systemic and immunological responses including fever, 
rashes, peripheral neutrophil accumulation, increased cytokine production (IL-2,-3,-4,-5,-
6,-7,-10,-12), elevated antibody production and enhanced infiltration of immune effector 
cells into inflammatory sites, etc.  Mice deficient in IL-1β are completely resistant to LPS-
induced endotoxin shock. In humans, overproduction of IL-1β plays a critical role in sepsis. 
Along the same line, dysregulated secretion of IL-1β causes devastating systemic 
inflammatory disease such as SoJIA (also known as systemic onset juvenile idiopathic 
rheumatoid arthritis). Moreover, the symptoms of SoJIA patient can be rapidly and 
sustainablly resolved by the administration of IL-1β receptor antagonist (IL-1Ra, anakinra) 
(37). This evidence highlights the critical role of IL-1β in systemic inflammatory response 
and the importance of tight regulation of its secretion.  
The immune system imposes several regulatory mechanisms to prevent deleterious 
effects induced by the over-secretion of IL-1β. First, the transcription and translation of IL-
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1β are kept at extremely low levels and can only be drastically increased upon the cell 
receiving extracellular signals such as TLR signaling. Second, the IL-1β is synthesized and 
stored in the cytoplasm and secretory lysosomal vesicles are inactive precursors (proIL-1β, 
or IL-1βp35) that must be proteolyticaly cleaved into its active form (IL-1βp17). Third, the 
secretion of leaderless IL-1β is strictly controlled by a still poorly defined mechanism. 
Finally, a constitutively secreted naturally occurring IL-1β receptor antagonist (IL-1Ra) 
binds type I IL-1β receptor with an affinity higher than that of IL-1β. Among these 
regulatory steps, the most critical one is the process that converts proIL-1β to IL-1β. This 
process is mediated by an enzyme identified as caspase-1 (also known as IL-1β-converting 
enzyme (ICE)). 
Caspase-1 is an aspartate-specific cysteine protease that consists of an N-terminal 
CARD domain and a C-terminal caspase domain. Caspse-1 has been demonstrated to play 
an vital role in the cleavage of proIL-1β and proIL-18. Recently, IL-33, a novel cytokine 
that is involved in generating a T helper type 2 cell response, has also been shown to be 
cleaved by caspase-1 (38). The evidence obtained in caspase-1 null mice definitely reveals 
the essential role of caspase-1 in the proIL-1β and proIL-18 processing. Namely, caspase-1 
null mice have a defect in the maturation of proIL-1β and proIL-18 and are resistant to a 
lethal dose of endotoxin treatment. Furthermore, the caspase-1 activity is also regulated by 
numerous endogenous proteins, including COP (Pseudo-ICE) (39), DASC (POP1), 
ICEBERG (40), and human caspase-12. Caspase-1 itself exists in the cytosol as a 
monomeric zymogen (pro-caspase-1, p45). Upon certain stimulation, pro-caspase-1 
undergoes dimerization and autocatalytic processing that forms an active caspase-1. 
Interestingly, in addition to its well established role in the IL-1β maturation, a recent study 
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reveals a novel function of caspase-1 by demonstrating that the caspase-1 activates the 
central regulators of membrane biogenesis: the Sterol Regulatory Element Binding 
Proteins (SREBPs) (41), which in turn promote cell survival upon toxin challenge possibly 
by facilitating membrane repair. 
What are the external or internal signals that lead to the activation of caspase-1? 
How is caspase-1 activated? Towards answering the first question, there is evidence that 
LPS, a Gram-negative cell wall components and a major bacteria PAMP, can activate 
caspase-1 in phagocytes (42, 43). There are also extensive data to demonstrate that 
exposing cells to extracelluar ATP in vitro leads to caspase-1 activation (44, 45). 
Extracellular ATP binds to P2X7 receptor, which is a membrane ion channel responsible 
for the potassium efflux (46). Thus, the extracellular ATP, released by membrane-
compromised cells, might serve as a ‘danger signal’ to alert  neighboring cells. 
Towards answering the second question, the major breakthrough comes from a 
seminal biochemical study demonstrating that caspase-1 is activated by a multi-protein 
complex termed ‘inflammasome’ (modeled from Apoptosome). This complex is comprised 
of caspase-1, caspase-5, ASC (apoptosis-associated speck-like protein containing a CARD; 
also known as CARD5, Pycard, and TMS1), and NALP1/NLRP1 (47). Upon stimulation, 
NALP1 recruits adaptor protein ASC. The NALP1/ASC interaction initiates a self-
oligomerization process that forms a five or seven-fold symmetry structure that allows the 
further recruitment of caspase-1 and caspase-5. The exact mechanism regarding how 
caspase-1 becomes activated within this protein complex is still unknown but a close 
proximity-induced activation has been proposed. This study first demonstrates the 
inflammasome as the major molecular platform for caspase-1 activation and further 
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implicates the existence of inflammasomes formed by other NLR proteins, especially for 
those that are expressed highly in monocytes/macrophages such as cryopyrin/NLRP3 and 
Ipaf/NLRC4. Indeed, the cryopyrin and Ipaf inflammasomes are all demonstrated recently. 
However, the identification and characterization of those NLR inflammasomes in intact 
cells remain to be demonstrated and should drastically advances our knowledge in 
understanding the regulation of IL-1β secretion. 
1.2.1 The cyropyrin inflammasome  
Cryopyrin is a 118 KDa NLR protein encoded by gene CIAS1. Cryopyrin is 
comprised of an N-terminal pyrin domain, a central nucleotide binding domain and a C-
terminal LRR domain. In humans, mutations in CIAS1 are responsible for several 
autosomal dominant auto-inflammatory disorders. The initial overexpresison study 
indicated that human cryopyrin forms a inflammasome with ASC, Cardinal, and caspase-1 
(48). A subsequent study has shown that the bacterial peptidoglycans (PGN) product 
muramyl diapeptide (MDP) induces cryopyrin mediated activation of caspase-1 and 
maturation of proIL-1β in human THP-1 monocytic cell line (49). However, the role of 
MDP in cryopyrin-mediated IL-1 production was not found under physiologic conditions 
when CIAS1-/- mice were studied. 
 The physiological role of cryopyrin in caspase-1 activation is not firmly defined 
until recently by several studies using genetic approaches. First, it was reported that 
cryopyrin-deficient and ASC-deficient macrophages fail to activate caspase-1 in response 
to the treatment of LPS plus ATP. This result indicates that cryoprin is vital in LPS plus 
ATP stimulated caspase-1 activation (50) (51). Extracellular ATP binds its receptor P2X7, 
a potassium channel, and induces its rapid opening. The activated P2X7 also recruits a 
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hemichannel, pannexin-1, that gradually forms a larger membrane pore upon activation. 
Indeed, pannexin-1 has been recently demonstrated to play an essential role in cryopyrin 
induced caspase-1 activation (52). Further more, nigericin, a bacterially derived potassium 
ionophore and maitotoxin, a shellfish toxin , which induces the formation of plasma 
membrane pore and rapid potassium efflux, can activate caspase-1 in macrophages from 
WT mice but not from cryopyrin deficient mice (50). Along the same line, bacteria pore-
forming toxins such as Staphylococcus α-toxin and  Listeria aerolysin have been 
demonstrated to activate caspase-1 in a cryopyrin dependent manner in human THP-1 cells 
(41). Collectively, these data firmly demonstrate that ATP or pathogen induced potassium 
efflux are major stimuli in cryopyrin mediated inflammasome formation and caspase-1 
activation. Notably, it is initially thought that TLR signaling is critical for the ATP induced, 
cryopyrin dependent, caspase-1 activation due to the clear requirement of LPS. However, 
TLR4-/-, TLR2-/-, MyD88-/- and Ticam1-/- mice are all exhibit normal caspase-1 activity 
upon the treatment of heat killed bacteria and ATP (52). These data indicate that 
cryopyrin-dependent caspase-1 activation is independent of TLR signaling. However, TLR 
signaling might enhance the transcription of proIL-1β; therefore, priming the cells for ATP 
induced caspase-1 activation and IL-1β maturation. 
At least two additional stimuli can lead to the cryopyrin mediated IL-1β secretion. 
Martinon et al. reported that gout and pseudogout-associated uric acid crystals, namely, 
monosodium urate (MSU) and calcium pyrophosphate dihydrate (CPPD), activate caspase-
1 and induce maturation of IL-1β and IL-18 in a cryopyrin and ASC dependent manner 
(53). Blocking ATP receptor P2X7 has no effect on MSU and CPPD induced IL-1β 
secretion, suggesting this pathway acts independent of the ATP induced pathway. 
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Interestingly, colchicines, a tubulin polymerization inhibitor and a drug frequently used for 
the treatment of gout, completely blocks MSU induced maturation of IL-1β indicating that 
the activation of cryopyrin inflammasome might be mediated by microtube formation. 
Finally, cryopyrin inflammasome also responds to bacterial RNA and antiviral 
imidazoquinoline compounds R837 and R848, which are known TLR7 and TLR8 agonists 
(54). This R837 and R848 induced cryopyrin inflammasome activation is completely 
independent of TLR7 and TLR8 signaling. However, the role of ATP is dispensable. TLR 
ligands LPS and  Pam3csk4 alone can activate cryopyrin inflammasome without the 
addition of ATP (54) whereas, other groups demonstrates ultrapure LPS fails to do so. This 
discrepancy may be due to the subtle difference in cell preparation and stimulation 
protocol.  
Previously, MDP has been shown to activate caspase-1 through cryopryin 
inflammasome in human monocytic cell line (49). However, all studies of mice 
macrophages fail to confirm this result. Thus, the role of MDP in cryopryin-mediated 
caspase-1 activation remains to be seen. In addition, intracellular bacteria Listeria 
monocytogenes and Staphylococcus. aureus  induce cryopyrin dependent caspase-1 
activation and IL-1β maturation whereas Salmonella and Francisella do not. These results 
highlight the specificity of cryopyrin inflammasome (50). 
 What is the physiological role of cryopyrin in vivo? In a lethal LPS induced 
endotoxin shock model, while all wt mice succumbed to death with 48 hr, only 30% of 
cryropyrin-/- mice died after 72 hr. Correlating with their enhanced survival, cryopyrin 
deficient mice had significant less serum IL-1β and IL-18 than the wild-type mice (50). 
This result is echoed in another report which showed that cryopyrin deficient mice and 
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ASC deficient mice are protected from lethal dose of LPS (51). Interestingly, cryopyrin 
mice only show enhanced survival in a low lethal dose of LPS treatment (9.38mg/Kg), 
however, ASC deficient mice are resistant to death even with high-end lethal dose of LPS 
(37.5mg/Kg) indicating adaptor ASC might participates in additional inflammatory 
response. In these studies, ATP was not used. It is still not clear why cryopyrin-dependent 
inflammasome can be activated in vivo without the addition of ATP. It is possible that LPS 
treatment elicits ATP release from other cell types. Nevertheless, these results clearly 
demonstrate the role of cryopyrin activation and IL-1β maturation in vivo. Finally, the 
cryopyrin inflammasome has also been demonstrated to play an important role in 
mediating contact hypersensitivity,  a T cell mediated cellular immune response to 
repeated epicutaneous exposure to contact allergens. Suttutterwala et al sensitized and 
challenged wild type and cryopyrin deficient mice with trinitrophenylchloride (TNP-Cl). 
Significant ear swelling is evident in wt type mice but not in cryopyrin deficient mice and 
ASC deficient mice (51). 
All together, these results reveal the critical role of cryopyrin in caspase-1 
activation and IL-1β maturation in response to a variety of stimuli ranging from 
endogenous danger signals to pathogen derived products. However, the fact that cryopyrin 
deficiency only partially protects mice from lethal dose of LPS challenge, whereas ASC-/- 
and caspase-1-/- completely protect mice suggests the existence of other inflammasome 
activation pathways. 
1.2.2 The Ipaf inflammasome  
NLR protein NLRC4/Ipaf (ICE-protease activating factor also know as CARD12 
and CLAN) contains a CARD domain at its N-terminal. Ipaf deficient mice fail to activate 
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caspase-1 in response to Salmonella and Pseudomonas aeruginosa infection but remain 
responsive to LPS plus ATP induced caspase-1 activation. This result indicates that Ipaf 
inflammasome functions independent of cryopyrin inflammasome (55). It is has been 
known for a long time that the activation of caspase-1 by Samonella infection requires 
Salmonella SipB gene, a translocase of Salmonella type III secretion system (TTSS). The 
TTSS is encoded in the Salmonella pathogenicity island1 (SP1) and delivers effector 
proteins to the eukaryotic cell cytosol. Previously, it has been demonstrated that SipB 
protein directly binds and activates caspase-1 upon Salmonella infection (56). However, 
TTSS might inject a pathogenic effector into host cytosol that directly activates Ipaf 
inflammasome. Recently, two groups independently demonstrated that infecting mouse 
macrophage with Salmonella mutants that are deficient in flagellin fails to activate 
caspase-1. This result suggests that flagellin is the agonist for Ipaf (57, 58). Importantly, 
the flagellin-dependent activation of caspase-1 is not depend on TLR5 but requires the 
TTSS components SipB. In addition, direct intracellular deliver of flagellin by protein 
transfection activates caspase-1. Although flagellin relies on its own secretion system to 
assemble cell surface flagellum, it is temping to speculate that TTSS accidental delivers a 
small amount of flagellin into the cytoplasm of infected cells. However, the detailed 
mechanism of how Ipaf inflammasome senses flagellin requires further elucidation. 
1.2.3 The NALP1 inflammasome  
NALP1 (CARD7, DEFCAP, NLRP1) inflammasome is the first prototypical 
inflammasome discovered five years ago. By using THP-1 cell lysate, Martinon et al 
demonstrated that human NALP1 inflammasome consists of NALP1, ASC, caspase-5 and 
caspase-1 (47). However, the cell lysate system used by this study cannot preclude the 
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possibility that additional components participate in the NALP1 inflammasome. To define 
the minimal components of NALP1 inflammasome and to further characterize its 
biochemical properties, Faustin et al. reconstituted the NALP1 inflammasome in vitro by 
using purified recombinant proteins (59). They demonstrated that the minimal components 
of NALP1 inflammasome are NALP1 and caspase-1. More importantly, they showed that 
activation of NALP1 inflammasome requires the presence of ribonucleotide, especially, 
ATP. This result indicates that ATP binding and hydrolysis might play a critical role in the 
inflammasome activation (59). Since NALP1 is the only protein in this complex that 
possesses a conserved NTP binding domain, we can hypothesize that the ATP binding to 
NALP1 plays a critical role in the NALP1 oligomerization and activation. This proposed 
mechanism of inflammasome formation is reminiscent of apoptosome formation. However, 
evidence for the direct binding of nucleotides to NALP1 is absent in their study. Faustin et 
al also demonstrated that the addition of other nucleotides such as GTP and CTP activate 
the inflammasome. It is currently unknown why the binding of NALP1 to nucleotide 
shows no specificity. Moreover, Faustin et al demonstrated that bacteria cell wall 
component MDP strongly activates caspase-1 in the reconstituted NALP1 inflammasome 
(59). However, direct binding of MDP to NALP1 was not demonstrated. Previously, MDP 
has been shown to activate human cryopyrin in THP-1 cell lysate system, although this is 
controversial. MDP is also a well-known agonist for NOD2. The underlying mechanisms 
of how MDP stimulates each pathway require more detailed biochemical analysis and the 
use of physiologic systems similar to what has been achieved for NOD2. 
What is the physiological role of NALP1 inflammasome in vivo? In genetic 
analysis, Boyden and Dietrich demonstrated that a genetic region containing the mouse 
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NALP1b gene is associated with the susceptibility to Bacillus anthracis lethal toxin (LT) 
(60). Bacillus anthrancis is the causative agent of anthrax.  Bacillus anthrancis secretes 
several virulence toxins including lethal toxin that is thought to responsible for the 
mortality in systemic anthrax episodes. Macrophages from different inbred mice have 
different susceptibilities to anthrax LT. The LT susceptibility has been mapped to Ltxs1 
locus. There are three tandem Nalp1 paralogues (Nalp1a, 1b, 1c) in Ltxs1 locus, but only 
Nalp1b is actively transcribed in mice macrophages. Nalp1b itself is highly polymorphic 
with 5 distinct Nalp1b alleles identified. Strikingly, eight of nine LT-sensitive strains carry 
only one of these five alleles, designed allele 1, whereas the nine LT-resistant strains carry 
allele 2, 3 or 4.  BAC transgenic mice that carry the sensitive allele 1 on a resistant 
background confer LT sensitivity. Furthermore, upon toxin exposure, caspase-1 is only 
activated in LT sensitive strain and transgenic mice carrying allele1, but not in LT resistant 
strain. This study strongly demonstrates the role of NALP1 in anthrax pathogenesis. 
Intriguingly, the locus responsible for familial vitiligo has been demonstrated to contain 
NALP1 (61). Vitiligo is a chronic skin condition that causes loss of pigment, resulting in 
irregular pale patches of skin. Although the etiology of the disease is complex and not fully 
understood, there is some evidence suggesting it is caused by a combination of 
autoimmune, genetic, and environment factors. It is now highly possible that specific 
mutants of NALP1 are responsible for vitiligo. 
1.2.4 NAIP inflammasome 
NAIP ( Baculovirus IAP containing 1, also known as Birc 1, Baculovirus inhibitor 
of apoptosis repeat-containing 1) is an unique NLR protein that contains three N-terminal 
BIR domains in its N-terminal instead of more commonly presented pyrin or CARD 
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domain. Early high-resolution genetic and physical mapping have implicated mouse Naip2 
and Naip5 in Legionella pneumophila-induced pathogenesis (62), while others used a BAC 
rescue approach and found that Naip5 is the gene that confers resistance or susceptibility to 
the pathogen (63, 64). Later, it was found that Naip5 is required for the restriction of 
Leginella replication in macrophages, in a caspase-1 dependent fashion, and this restriction 
requires the Legionella flagellin (34, 65, 66). However, another group has found that Naip5 
restricted Legionella pneumophila proliferation by Naip5 is caspase-1 independent while 
its restriction by Ipaf is caspase-depent and flagellin-dependent (67, 68). The conflicting 
nature of these data remain to be solved, however they point to the roles of NAIP and Ipaf 
inflammasome in host defense against L.pneumophila  
Besides the inflammasome pathways described here, there are likely other 
inflammasome pathways. Indeed, the NLR protein that accounts for Francisella tularensis 
induced IL-1β activation remains unknown. Francisella tularensis is Gram-negative 
coccobacillus and the causative agent for the zoonotic disease tularaemia or ‘rabbit fever’. 
It has been demonstrated that F. tularensis infection results in the activation of caspase-1 
and maturation of IL-1β in an ASC dependent fashion (69). Caspase-1 deficient and ASC 
deficient mice were highly susceptible to the F.tularensis infection in vivo (69). However, 
F.tularensis induced caspase-1 has not been shown to depend on cryopryin and Ipaf. 
Therefore, an unidentified NLR molecule might link the F .tularensis-derived signals to an 
ASC containing inflammasome in response to cytosolic F .tularensis. 
1.2.5 Summary 
In the last three years, we have witnessed a tremendous progress in understanding 
the regulation of IL-1β secretion.  To date, the essential role of NLRs (including cyropryin, 
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Ipaf, NALP1) in the assembly of inflammasome and the activation of caspase-1 is defined. 
The field has also identified numerous agonist/stimuli that lead to the activation of 
inflammasome. What we have not learned is the detail mode of actions. For instance, we 
do not know how decreased intracellular potassium level is sensed by cryopryin 
inflammasome. We do not know how Ipaf recognizes flagellin. Is it through a direct 
binding or through an intermediate protein? Furthermore, are there undetermined 
inflammasome pathways? Do different cell types preferentially use particular 
inflammasome pathway?  Is individual NLR mediated inflammasome functionally 
redundant or overlapping during pathogen infection? How is caspase-1 cleaved after being 
recruited to the inflammasome? What is the role of nucleotide binding/hydrolysis in 
inflammasome assembly? These questions cannot be answered only by using genetic 
approaches. The field needs elaborate biochemical studies to define the mechanisms. 
Moreover, most genetic studies of inflammasome activation are done in murine 
monocytes/macrophages. So, can human primary cells recapitulate the results obtained in 
mice? Future studies need to focus on primary human cell culture or even humanized mice 
to address these questions. 
1.3 The role of NLR in cell death  
Cell death exists in multiple forms, the most prominent being apoptosis or necrosis 
(70). Apoptosis is a morphological and biochemical distinct death process and has been 
shown to play an essential role in cell differentiation and tissue development. Cells 
undergoing apoptosis display distinct morphologies such as extensive chromatin 
condensation, nuclear fragmentation, cleavage of chromosomal DNA into nucleosomal 
fragments and forming of the dead cell into apoptotic bodies without cell membrane 
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breakdown. The signaling pathways that lead to apoptosis are now detailed studied and are 
mediated by the activation of caspase cascade. On the other hand, necrosis, or more 
accurately ‘oncosis’, is described as an accident and non-programmed event that is  
triggered by a sudden external insult. Cells undergo necrosis often display cell and 
organelle swelling and rapid loss of membrane permeability(70, 71). 
Bacteria infection not only leads to inflammatory response but also cell death. 
These two processes are not isolated events but are interconnected phenomena. 
Inflammation induced cell death, especially necrosis, causes the release of a large amount 
of cellular substances that are strong stimuli of inflammation. Therefore, it forms a positive 
feed back loop that boosts the magnitude and sustains the duration of an inflammatory 
response. Inflammation induced cell death can be beneficial to the host because it removes 
the host cells that are infected by microbial pathogen, therefore, eliminating the host 
environment that propagates the pathogen. On the other hand, inflammation induced cell 
death can be detrimental to the host, because an overzealous inflammatory response might 
results in significant damage to the host, as in the case of sepsis. 
 Salmonella typhimurium and Shigella flexneri, two enteric bacteria with distinct 
characteristic and pathogenic outcome, are the prototypic bacteria that induce cell death 
(72). Initial studies showed that Salmonella infection leads to a caspase-1 dependent cell 
death both in vitro and in vivo. This death process is unique in that it morphologically 
differs from the classical apoptosis and is often manifested by a rapid loss of membrane 
integrity, a hallmark of necrosis. This necrosis like, caspase-1 dependent death process is 
subsequently termed ‘pyroptosis’(71). Furthermore, the Salmonella induced cell death has 
been shown to require the Salmonella SipB protein, a component of type III secretion 
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system. An initial study demonstrated that SipB directly binds caspase-1 and mediates its 
activation (56). A subsequent study revealed that NLR protein Ipaf and adaptor ASC are 
required to mediated Salmonella induced caspase-1 activation and cell death. The later 
study formally delineates the important role of NLR protein in initiating pathogen induced 
death process. However, a Salmonella induced, caspase-1 independent cell death is also 
reported (73). 
Early studies revealed that Shigella infection triggers caspase-1 dependent 
apoptosis while other groups subsequently described a form of Shigella induced death that 
is caspase-1 dependent and necrotic in nature. How Shigella infection leads to the 
activation of caspase-1 is largely unknown until a recent study by Suzuki et al showed that 
Ipaf and ASC are required for  Shigella induced caspase-1 activation (74). Interestingly, 
while Ipaf is required for both Shigella induced caspase-1 and initial cell death process, 
ASC is completely dispensable in the Shigella induced cell death, yet it is absolutely 
required for caspase-1 activation (74). In addition, Suzuki et al demonstrated that Ipaf 
deficient mice and caspase-1 deficient mice still undergo cell death even though the initial 
death progress is significantly delayed (74). This data clearly demonstrates the existence of 
a caspase-1 independent death process in Shigella infection that happens concurrently 
along with the caspase-1 dependent death. Indeed, Willingham et al recently reported that 
Shigella infection leads to a rapid necrosis-like cell death in mice macrophages that is 
independent of caspase-1 but dependent on cryopryin and ASC. They termed this caspase-
1 independent necrosis like cell death as ‘pyronecrosis’. This result is in line with a 
previous study showing that the cytosolic Shigella induced a caspase-1/TLR4 independent 
necrosis-like cell death in macrophages (75). In sharp contrast to study from Suzuki et al, 
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Willingham et al also demonstrated that Shigella induced caspase-1 activation is depend on 
cryopyrin instead of  Ipaf. This is in sharp contrast to Suzuki et al ‘s study. This 
discrepancy might be attributed to the subtle difference of bacteria strain and experiment 
conditions. Therefore, both forms of inflammasome might be produced upon Shigella 
infection. 
CIAS1/Cryopyrin mutations are associated with several autoinflammatory disorder: 
FCAS, MWS and CINCA/NOMID. To evaluate the potential role of cryopyrin induced 
cell death in the pathogenesis of those diseases, Fujisawa et al transfected human THP-1 
monocytic cell line with disease associated CIAS1 mutants. They demonstrated that 
overexpression of these mutants induced a rapid necrosis-like cell death (76). This 
necrosis-like cell death can be blocked by the inhibitor for cathepin B, a lysosomal enzyme 
that nonspecifically digests protein within the lysosomal compartment. This result 
indicated that the cryopryin induced necrosis-like death undergoes a cathepsin B dependent 
pathway. 
Subsequently, Willingham et al demonstrated a similar necrosis-like death process 
in THP-1 cells infected by adenovirus encoding CIAS1 disease-associated mutants. Similar 
to the Shigella induced death, this CIAS1 mutants induced necrosis-like cell death is 
independent of caspase-1. Importantly, the authors also showed that peripheral blood 
mononuclear cells (PBMC) from FCAS patients undergo significant cell death under LPS 
treatment. Together, these data combined with previous studies demonstrate that cryopyrin 
disease-associated mutants not only enhance the caspase-1 activation but also induce a 
rapid necrosis-like cell death, both processes might all contribute to disease state in 
patients. 
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In summary, accumulating evidences demonstrate the important role of NLRs in 
mediating caspase-1 dependent or independent cell death. Of note, a recent study 
demonstrated that  activated ASC oligomerized into a 1μm supermolecular complex 
termed ‘pyroptosome’, which can mediate caspase-1 dependent cell death (77). 
Nevertheless, how the activation of caspase-1 leads to cell death remains elusive. 
1.4 The role of NLR in the intracellular sensing of pathogen-derived 
molecules 
The NLRs that have been first demonstrated to detect intracellular PAMP are 
NOD1 (CARD14) and NOD2 (CARD15). NOD1 and NOD2 both have typical NLR 
protein domain arrangement that consists of C-terminal LRR, N-terminal CARD domain 
and central NBD domain. NOD1 have one CARD domain at its N-terminal whereas NOD2 
have 2 tandem CARD domains. NOD 1 and NOD2 are required for cellular response to 
peptidoglycan, a component of both Gram positive and negative bacteria. Specifically, the 
ligands for NOD1 and NOD2 is γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and 
muramyl dipeptide (MDP), respectively. Of note, iE-DAP is only derived from Gram 
negative bacteria, whereas MDP is derived from both Gram positive and negative bacteria 
suggesting that NOD1 only senses products from Gram-negative bacteria and NOD2 
detects both type of bacteria. Nevertheless, evidence demonstrating the direct binding of 
NOD1, NOD2 by their cognate ligands are still lacking. NOD1 has a wide tissue 
distribution while NOD2 are primary expressed by macrophages and dendritic cells. 
Although NOD1 and NOD2 mainly reside in cytosol, NOD2 has been demonstrated to 
associate with plasma membrane in epithelial cells (78). 
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Upon their cognate ligand stimulation, NOD1 and NOD2 activate a CARD 
containing serine/threonine kinase RIP2 (also known as RICK). The activation of RIP2 
leads to a K63-linked polyubiquitylation of NEMO (IKKγ), which triggers the activation of 
IKKβ and NF-κB translocation (79). In addition to the activation of NF-κB, NOD1 and 
NOD2 signaling also activate MAP Kinase pathways such as JNK (JUN amino-terminal 
kinase), ERK (extracellular-signal-regulated kinase (ERK) and p38. Previous study 
demonstrates that RIP2 is also used by TLR signaling pathway due to the data showing 
that RIP2 deficient mice show reduced cytokine secretion upon LPS and lipoteichoic acid 
stimulation (80). However, by using highly purified and synthetic TLR ligand, Park et al 
showed that the TLR signaling pathways are mostly intact in RIP2 deficient mice 
suggesting that RIP2 is only used by NOD1 and NOD2 signaling pathway (81). In addition, 
NOD2 mediated signaling is regulated by its binding partners. For example, GRIM-19, a 
protein with homology to the NADPH dehydrogenase complex, interacts with NOD2 and 
is required by NOD2 mediated NF-κB activation (82). Erbin, a member of LRR and PDZ 
domain-containing family, has been shown to interact with NOD2. Interestingly, Erbin 
functions as a negative regulator of NOD2 mediated signaling(83) (84).  
NOD1 and NOD2 are thought to be the intracellular bacteria sensor. The activation 
of NOD1 and NOD 2 elicit a strong production of proinflammatory cytokine such as IL-6, 
TNF-α and the induction of antimicrobial peptides such as β-defensin and cryptdins. 
Kobayashi et al reported that mice deficient in NOD2 fail to respond to MDP indicating 
the specificity of NOD2/MDP detection (85). Moreover, NOD2 deficient mice are 
susceptible to oral infection of Listeria Monocytogene suggesting the critical in vivo role 
of NOD2 in anti bacteria host defense (85). This study also implies that the Crohn’s 
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disease associated NOD2 mutations are loss-of-function mutations and that the 
nonfunctional NOD2 mutants might result in defective response to commensal and 
pathogenic bacteria. However, Watanabe and Strober et al have shown that, in NOD2 
deficient mice, the secretion of IL-12, a cytokine critical in the development of T help cells 
type 1 response, is significantly increased upon TLR2 stimulation. This result suggests that 
NOD2 actually functions as a negative regulator of TLR2 signaling (86). Furthermore, in a 
subsequent study,  Watanabe et al demonstrated that NOD2 deficient mice develop colitis 
in an E.coli induced colitis model (87) implying that the Crohn’s disease-associated 
mutants fail to control TLR2 signaling leading to an elevated inflammatory response. Thus 
this also suggests disease-associated mutants as loss-of-function mutant, but the underlying 
mechanism is drastically different. This discrepancy awaits further clarification in future 
study. 
Finally, Maeda et al generated a Crohn’s disease (CD) mutant knock-in mice and 
demonstrated that the CD mutant Knock-in mice exhibits elevated NF-κB activation in 
response to MDP and enhanced secretion of IL-1β (88). This study indicates the CD 
associated mutant is a gain-of-function mutant and seemingly fits the massive 
inflammation observed in CD patient. However, this study is in sharp contrast to the in 
vitro studies from human monocytes bearing NOD2 disease associated mutant, which 
show abolished MDP sensing and synergy with TLRs. Clearly, more efforts need to be 
made to address the mechanisms of NOD2 mutants in Crohn’s disease pathogenesis. 
1.5 The biological function of NLR protein, Monarch-1/NLRP12 
1.5.1 Canonical and non-canonical NF- κB signaling pathway 
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NF-κB is a dimeric transcription factor consisting of p50, p52, Rel-A (also known 
as p65), Rel-B and c-Rel. p50 and p52 are derived from the larger precursors p105 (NF-
κB1) and p100 (NF-κB2), respectively, through proteolytic processing by the proteasome. 
The most common dimeric forms of NF-κB are p50/Rel-A and p52/Rel-B. 
In the resting state, the NF-κB proteins are sequestered in the cytoplasm by the IκB 
(Inhibitor of κB) proteins that include IκBα, β and ε. Upon activation, The IκB is subjected 
to K48-linked ubiquitination and subsequent degradation by proteosome. This process 
liberates the NF-κB dimers that then translocate into the nucleus to initiate gene 
transcription. The NF-κB signaling pathway can be generally divided into the canonical 
and the non-canonical pathway. 
The TLR signaling leads to the activation of canonical NF-κB pathway. Upon 
engaged by its cognate agonist, TLR dimerizes and recruits adaptor protein such as 
MyD88 through TIR-TIR domain interaction.  The recruitment of MyD88 activates kinase 
IRAK-4 (interleukin-1 receptor-associated kinase-4) that subsequently phosphorylates its 
downstream target IRAK-1. The phosphorylated IRAK-1 undergoes further self-
phosphorylation and activates an ubiquitin E3 ligase TRAF6. Activated TRAF6 recruits 
ubiquitin E2 complex consisting of Ubc13 and an Ubc-like Uev1A. This process 
synthesizes a K63-linked polyubiquitin chain on IKKγ (NEMO) and TRAF6 itself.  The 
ubiquitinated TRAF6 recruits TAB2 and activate the TAB2-associated TAK1 kinase. 
Activated TAK1 then phosphorylates, and activates IKKβ, which phosphorylates IκB 
protein leading its degradation. The ubiquitination plays a critical role in the activation of 
canonical NF-κB pathway and therefore is tightly regulated by the deubiquitination process 
mediated by CYLD (cylindromatosis tumor suppressor protein) and A20.  
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The non-canonical NF-κB pathway operates in response to stimulation of a subset 
of the TNF receptor superfamily, including receptors for lymphotoxin-β (LTβ), BAFF and 
CD40 ligand. Stimulation of these receptors activates the protein kinase NIK (NF-κB 
inducing Kinase), which in turn activates IKKα. IKKα then phosphorylates p100 leading to 
the selective degradation of its IκB-like domain by the proteasome. The mature p52 
subunit and its binding partner Rel-B translocate into the nucleus to regulate gene 
expression. 
1.5.2 Monarch-1 is a negative regulator of both canonical and non-
canonical NF-κB pathway 
By data mining the human genome, our group first identified a novel gene family 
termed CATERPILLER, which now named as NLR protein family. One of the novel 
members of this protein family is Monarch-1, which was cloned by our group using 5' and 
3' RACE reaction that amplified cDNA from human U937 monocytic cell line (89). 
Concurrently, another group also identified the same cDNA sequence named PYPAF7 
(90). The full-length cDNA of Monarch-1 is 3731-bp long with a 220-bp 5'UTR, a 323-bp 
3'UTR and a 3189-bp open reading frame encoding a 118 KDa Monarch-1. It is located on 
human chromosome 19q13.4. 
Monarch-1 is expressed predominantly in cells of the myeloid lineage, including 
monocytes and granulocytes. Furthermore, single nucleotide polymorphism analysis has 
recently demonstrated a genetic link between Monarch-1 and atopic dermatitis (91). 
However, in contrast to most NLR proteins that promote inflammation, Monarch-1 
functions as an attenuator of inflammatory responses. Monarch-1 inhibits TLR-mediated 
hyperphosphorylation of IRAK-1, a necessary step in TLR signaling pathways (92). In 
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addition, Monarch-1 binds to and destabilizes the MAP3 kinase, NIK and blocks NIK-
mediated processing of NF-κB2/p100 to p52 (93). The p52 subunit is an important 
downstream mediator of signaling by TLRs as wells as TNF family receptors including 
CD40 and lymphotoxin-β receptor. The introduction of shRNA specific for Monarch-1 
greatly enhances NF-κB activation and the transcription of NIK-dependent genes induced 
by TLR and TNF family receptor activation. These earlier studies suggest that Monarch-1 
performs important anti-inflammatory roles as an inhibitory molecule of innate immune 
activation (Figure 1-2). 
1.6 The role of Nucleotide binding in the biological function of NLR 
The nucleotide binding domain of NLRs belongs to the AAA+ (ATPases associated 
with various cellular activities) ATPase protein family that also includes plant R protein 
and mammalian apoptotic protein Apaf-1 (apoptotic protease-activation factor 1) (94). 
AAA+ ATPase family is a functionally diverse group of enzymes that are able to induce 
conformational changes in a wide range of substrate proteins. The defining feature of 
AAA+ protein family protein is the structurally conserved ATP-binding and hydrolysis 
domain (AAA domain) that generally contains 200-250 amino acids. This domain contains 
two well-conserved motifs called Walker A and Walker B motifs (95). The structure of 
AAA domain comprises a compact core structure with five β-sheets sandwiched by six α-
helix fold. This core structure is followed by a C-terminal α-helical subdomain. For 
example, the crystal structure of  a AAA+ protein NSF (N-ethylmaleimide-sensitive factor) 
AAA domain is showed in (Figure 1-3A)(96). The Walker A motif (also called p-loop) 
comprises the consensus sequence GxxxxxGK[T/S] (where x is any amino acid and has 
been implicated to interact with the phosphate moiety of ATP directly. The lysine residue 
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in the consensus sequence is essential in coordinating the β and γ phosphates of ATP. 
Mutation of this key residue typically eliminates nucleotide binding activity (97). The 
Walker B motif also contacts with nucleotide and is crucial for ATPase activity. The 
Walker B motif contains a consensus sequence hhhhhDE (h represents a hydrophobic 
amino acid). The aspartic acid residue in the Walker B motif coordinates Mg2+ that is 
required for stable ATP binding and the glutamate residue is thought to be responsible for 
β-γ phosphodiestor bond breakage during ATP hydrolysis (97, 98). AAA+ proteins also 
contain a conserved region that is positioned C-terminal of the Walker-B motif and is 
named the second region of homology (SRH). The SRH comprises several conserved 
motifs including Sensor 1, Sensor 2, and arginine fingers, which all have been proposed to 
coordinate nucleotide hydrolysis and conformational changes. AAA+ protein typical 
oligomerized into a six or seven-fold symmetry multimer. It is clear now that the 
conformational changes required for oligomerization are driven by ATP binding and/or 
hydrolysis (97).  
Due to the sequence similarity between the NLR protein family and AAA+ ATPase 
family, I hypothesized that NLR protein binds and hydrolyze ATP and this process plays a 
critical role for the biological function of NLR. 
Although, there is no evidence that clearly demonstrates nucleotide binding and its 
role in NLR protein function when this thesis study is initiated, studies on nucleotide 
binding of closely related protein Apaf-1 and plant R protein strongly support my 
hypothesis.  
For example, the functional role of ATP binding and hydrolysis is clearly 
demonstrated in the study of mammalian Apaf-1 that plays a vital role in the execution of 
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intrinsic apoptosis pathway (99-101). Structurally similar to NLR protein, Apaf-1 is 
composed of an N-terminal CARD domain, a central nucleotide binding and 
oligomerization domain (called NB-ARC) (102) and a C-terminal multiple WD40 repeats. 
In a non-apoptotic condition, Apaf-1 resides in cytosol as an inactive monomer. During 
early apoptosis process, mitochondria cytochrome C specifically binds Apaf-1. In the 
presence of the dATP, the binding of cytochrome C induces a conformational change that 
triggers the oligomerization of Apaf-1/cytochrome C to form a wheel-like heptomeric 
structure termed ‘Apoptosome’.  The core of this wheel-like structure contains seven Apaf-
1 N-terminal CARD domains. The formation of this complex allows interaction of pro-
caspase-9 with Apaf-1 through the interaction of its own CARD with the CARD of Apaf-1, 
thus placing individual pro-caspase-9 molecules in close proximity with one another and 
promoting their activation (101, 103-105). 
Recent detailed biochemical and structural studies start to reveal the detailed mode 
of action in the assembly of Apoptosome and the critical role of ATP binding/hydrolyzing 
in mediating this process (106, 107). In the non-apoptotic state, WD40 domain of Apaf-1 
folds back on the NBD and CARD domain, resulting in an inactive monomer. ESI-Mass 
spectrometry analysis of purified Apaf-1 protein generated from insect cells reveals that 
inactive Apaf-1 is bound by dATP. Upon the induction of apoptosis, the binding of 
cytochrome C to the WD40 domain liberates the NBD domain from the inhibition of 
WD40 domain. Apaf-1 then hydrolyzes the bound dATP and undergoes a conformational 
change. Critically, only if the bound dADP is subsequently exchanged with 
exogenous dATP, does form the active Apoptosome with ordered structure. If the 
concentration of cellular dATP is insufficient for nucleotide exchange after hydrolysis, the 
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dADP bound Apaf-1 oligomerizes into an inactive aggregates (Figure 1-3B). Currently, we 
do not yet know the precise binding site of cytochrome c on Apaf-1 nor do we know how 
dADP is exchanged for dATP after the initial hydrolysis of dATP. Furthermore, the crystal 
structure of WD-40-truncated Apaf-1 reveals that the inactive Apaf-1 binds an ADP but 
not dADP. This crystal structure is obtained from bacteria derived Apaf-1 protein. It is 
unknown why the bacteria-derived Apaf-1 prefers ATP instead of dATP as cofactor. We 
also do not know whether endogenous Apaf-1 in mammalian cells also exclusively binds 
dATP. Nevertheless, the ATP hydrolysis/exchange driven oligomerization shown in Apaf-
1 provides us a prototype for understanding the role of nucleotide binding in NLR function. 
Plant disease resistant R proteins are also highly homologous to NLR protein. Like 
NLR protein, Plant R protein also contains a central nucleotide binding domain (called 
NBD-ARC) and C-terminal LRR. Plant R protein mediates Hypersensitivity Reaction (HR) 
upon encountering their cognate agonist. The nucleotide binding and its functional role in 
R protein are recently revealed by studies on tomato R protein I-2 that confers resistance to 
the fungal pathogen Fusarium oxysporus. It has been demonstrated that purified LRR 
truncated I-2 protein binds ATP. The binding is abolished when mutation is introduced to 
Walker A motifs (108). Furthermore, purified I-2 protein also exhibits ATP hydrolysis 
activity. This result shows that I-2 is a bona fide ATPase. Two auto-activation mutants of 
I-2 protein are identified that lead to HR in the absence of an effectors. In a subsequent 
study, when a Walker A mutation was introduced in the context of autoactivation mutant, 
the double mutant completely abolished the HR reaction caused by overexpression of 
autoactivation mutant (109). This result indicates that the nucleotide binding is required for 
the plant hypersensitivity reaction. 
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Before the discovery of the CATERPILLER protein family, our lab also discovered 
that the founding member of CATERPILLER protein family CIITA binds GTP, albeit the 
GTP binding activity is demonstrated by CIITA protein immunoprecipitated from an in 
vitro protein translation system. Importantly, the disruption of nucleotide binding pocket 
completly rescinds the CIITA nuclear import highlighting the critical role of GTP binding 
in mediating CIITA nucleus import (110). 
1.7 Summary and future direction 
Great strides are made in understanding the function of NLR protein in the past few 
years. The entire family has been identified and the key functions of several prominent 
NLR family proteins have been defined by over-expression, gene deletion and gene 
knockdown approaches. Several agonists and stimuli that lead to the activation of NLR 
have been identified and several key adaptors that are critical in the NLR signaling 
pathway have been found. The majority of NLR proteins appears to specialize as 
intracellular pathogen sensors and can mount strong inflammatory response upon the 
recognition of their cognate agonists; We also can raise several examples to show that 
NLR protein can also dampen the inflammatory response. 
However, many key questions regarding to the function of NLR protein are still left 
unanswered. To date, we have not obtained any crystal structure of NLR protein. Equally 
lacking is the experimental data demonstrating the biochemical mode of action regarding 
the “sensing” of pathogen products, proposed nucleotide-driven conformation change and 
signaling complex assembly. This knowledge cannot come solely by well-tailored genetic 
approaches but can only be obtained by sophisticated biochemical approaches. 
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 New approved 
symbol  
Other names and aliases  Domain organization  
CIITA C2TA (CARD)-AD-NACHT-NAD-LRR 
NAIP BIRC; CLR5.1  BIR3x-NACHT-NAD?-LRR  
NOD1 CARD4; CLR7.1 CARD-NACHT-NAD-LRR 
NOD2 CARD15; CD, BLAU, IBD1, PSORAS1; CLR16.3 CARD2x-NACHT-NAD-LRR 
NLRC3 NOD3; CLR16.2 CARD-NACHT-NAD-LRR 
NLRC4 CARD12; CLAN; CLR2.1, IPAF CARD-NACHT-NAD-LRR  
NLRC5  NOD27; CLR16.1 CARD-NACHT-NAD-LRR  
NLRX1  NOD9; CLR11.3 X-NACHT-NAD-LRR  
NLRP1  NALP1;  DEFCAP; NAC; CARD7; CLR17.1 PYD-NACHT-NAD-LRR-FIIND-CARD 
NLRP2  NALP2; PYPAF2; NBS1; PAN1; CLR19.9 PYD-NACHT-NAD-LRR 
NLRP3  CIAS1; PYPAF1, Cryopyrin; CLR1.1, NALP3 PYD-NACHT-NAD-LRR 
NLRP4  NALP4; PYPAF4;PAN2; RNH2; CLR19.5 PYD-NACHT-NAD-LRR 
NLRP5  NALP5; PYPAF8; MATER, PAN11; CLR19.8 PYD-NACHT-NAD-LRR 
NLRP6  NALP6; PYPAF5; PAN3; CLR11.4 PYD-NACHT-NAD-LRR 
NLRP7  NALP7; PYPAF3; NOD12; PAN7; CLR19.4 PYD-NACHT-NAD-LRR 
NLRP8  NALP8; PAN4; NOD16; CLR19.2 PYD-NACHT-NAD-LRR 
NLRP9  NALP9; NOD6; ; PAN12; CLR19.1 PYD-NACHT-NAD-LRR 
NLRP10  NALP10; PAN5; NOD8; Pynod; CLR11.1 PYD-NACHT-NAD 
NLRP11  NALP11; PYPAF6; NOD17; PAN10; CLR19.6 PYD-NACHT-NAD-LRR 
NLRP12  
NALP12; PYPAF7; Monarch1; RNO2; PAN6; 
CLR19.3 PYD-NACHT-NAD-LRR 
NLRP13  NALP13; NOD14; PAN13; CLR19.7 PYD-NACHT-NAD-LRR 
NLRP14  NALP14; NOD5; PAN8; ; CLR11.2 PYD-NACHT-NAD-LRR 
Table 1-1 The Nomenclature of NLR protein family 
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Table 1-1 The HUGO recommended Nomenclature for NLR protein family. 
The gene names used in this thesis are highlighted. The domain structures of each gene are 
listed. PYD: Pyrin domain; NACHT: NAIP, CIITA, HET-E and TP1; CARD: caspase-
recruitment domain; NAD: NACHT associated domain; LRR: Lucine rich repeats. 
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Figure 1-1 The biological function of NLR protein. A. The role of NLR protein in 
the secretion of proinflammatory cytokine IL-1β and IL-18. Several NLRs can form 
multi-protein complex called ‘inflammasome’. The inflammasome complex  recruits and 
activates caspase-1 that converts pro-IL-1β and pro-IL-18 to biological active IL-1β and 
IL-18, respectively. NLR protein cryopyrin senses the intracellular potassium efflux that is 
caused by the engagement of extracellular ATP on cell surface receptor P2X7.  The 
activation of P2X7 receptor also recruits cell membrane forming protein Pannexin-1, which 
further facilitates the potassium efflux. Bacteria pore forming toxin, viral RNA mimics 
R848, R837, gout-associated crystals as well as bacteria Listeria monocytogenes and 
Staphylococcus aureus all have been shown to activate cryopyrin inflammsome. Upon 
activation, Cryopyrin interacts with adaptor protein ASC through Pyrin-Pyrin domain 
interaction. ASC then recruits pro-caspase-1 through CARD-CARD domain interaction. 
This process leads to oligomerization and the activation of caspase-1. The bacteria product 
flagellin from Salmonella typhimurim and Shigella Flexneri activate Ipaf inflammasome. 
Flagellin produced by Legionella pneumonphila  activate NAIP5, which does not possess 
CARD or Pyrin domain, but is predicted to associates with Ipaf. It is not clear whether the 
Ipaf mediated inflammasome requires ASC. Anthrax lethal toxin activates NALP1 
infammasome, which requires adaptor ASC. B.  NOD2 mediated NF-κB activation. 
NOD2 can directly or indirectly detect bacteria cell wall components MDP. Upon 
detection, NOD2 recruits kinase RIP2/RICK, which subsequently ubiquitinates NEMO 
(IKKγ). The ubiquitination of NEMO results in the phosphorylation of IKKβ. This signal 
induced phosphorylation targets IκB for polyubiquitination and subsequent degradation by 
the 26S proteasome, thus releasing NF-κB. The p65/RelA dimer then translocates into the 
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nucleus and initiates the transcription of proinflammatory cytokines such as TNF-α and IL-
6.
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Figure 1-2 The function of Monarch-1 and the proposed role of nucleotide binding in NLR function. 
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Figure 1-2 The canonical and non-canonical NF-κB pathway and the biological 
function of Monarch-1. The TLR2 signaling leads to the activation of canonical NF-κB 
pathway. Upon engaged by its cognate agonist, TLR2 recruits adaptor protein such as 
MyD88 through TIR-TIR domain interaction.  The recruitment of MyD88 activates kinase 
IRAK-4 that subsequently phosphorylates its down stream target IRAK-1. The 
phosphorylated IRAK-1 undergoes further self-phosphorylation and activates an ubiquitin 
E3 ligase TRAF6.  TRAF6 recruits additional E2 ubiquitin ligase and synthesize a K63-
linked polyubiquitin chain on IKKγ (NEMO) and TRAF6 itself.  The ubiquitinated TRAF6 
recruits TAB2 and activate the TAB2-associated TAK1 kinase. Activated TAK1 then 
phosphorylates, and activates IKKβ, which phosphorylates IκB protein leading its 
degradation. The ubiquitination is tightly regulated by the deubiquitination process 
mediated by CYLD (cylindromatosis tumor suppressor protein) and A20. In human 
monocytes, Monarch-1 block the hyperphosphorylation of IRAK-1 therefore inhibits the 
canonical NF-κB pathway.  
The non-canonical NF-κB pathway operates in response to stimulation of a subset 
of the TNF receptor superfamily, including receptors for lymphotoxin-β (LTβ), BAFF and 
CD40 ligand. Stimulation of these receptors activates the protein kinase NIK, which in turn 
activates IKKα. IKKα then phosphorylates p100 leading to the selective degradation of its 
IκB-like domain by the proteasome. The mature p52 subunit and its binding partner Rel-B 
translocate into the nucleus to regulate gene expression. Monarch-1 interacts with NIK and 
decreases the stability of NIK, thus negative regulates the noncanonical NF-κB pathway. 
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Figure 1-3 The AAA+ ATP binding structure and Apoptosome formation 
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Figure 1-3 A. The crystal structure of AAA+ family protein NSF (N-
ethylmaleimide-sensitive factor). The PDB file of NSF (accession number:1D2N) was 
obtained form protein data bank . The crystal structure was rendered in King 2.12. Core 
structure for the nucleotide binding consists of five β-sheets sandwiched by six α-helixes. 
The position of Walker A, B motif and the bounded ATP and Mg2+ were indicated. B. The 
formation of Apoptosome.  The release of cytochrome C initiates the apoptosome 
formation. In non-apoptotic state, Apaf-1 exists as a dATP bound monomer. The CARD 
domain and WD40 domain folds back on the NBD domain of Apaf-1 render it inactive. 
The release cytochrome C interacts with WD40 domain leading to a change of 
conformation. The conformation change results further hydrolysis of bound ATP to ADP. 
The ADP bound Apaf-1 has to undergo one round ADP-ATP exchange to become fully 
activated. Activated Apaf-1 oligomerized into a wheel-like heptamer structure with CARD 
domain presented in the center of the structure. The structure then recruits and activates 
caspase-9, thus activates apoptosis process. 
Chapter 2 ATP binding by Monarch-1/NLRP12 is critical for its 
inhibitory function 
ABSTRACT 
The recently discovered Nucleotide Binding Domain-Leucine Rich Repeat (NLR) 
gene family is conserved from plants to mammals and several members are associated with 
human autoinflammatory or immunodeficiency disorders.  This family is defined by a 
central nucleotide binding domain that contains the highly conserved Walker A and 
Walker B motifs.  Although the nucleotide binding domain is a defining feature of this 
family, it has not been extensively studied in its purified form.  In this report, we show that 
purified Monarch-1/NLRP12, an NLR protein that negatively regulates NF-κB signaling, 
specifically binds ATP and exhibits ATP hydrolysis activity.  Intact Walker A/B motifs are 
required for this activity.  These motifs are also required for Monarch-1 to undergo self-
oligomerization, TLR- or CD40L- activated association with NIK and IRAK-1, 
degradation of NIK, and inhibition of IRAK-1 phosphorylation.  Stable expression of a 
Walker A/B mutant in THP-1 monocytes results in increased production of 
proinflammatory cytokines and chemokines to an extent comparable to cells in which 
Monarch-1 is silenced via shRNA.  The results of this study are consistent with a model 
wherein ATP binding regulates the anti-inflammatory activity of Monarch-1. 
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2.1 INTRODUCTION 
Nucleotide Binding Domain-Leucine Rich Repeat (NLR) proteins share strong 
structural homology to the largest subgroup of plant disease resistance (R) proteins. These 
proteins share a trimeric domain architecture consisting of an N-terminal effector domain, 
a central nucleotide binding domain (NBD) and C-terminal leucine rich repeats (LRR).  
Mounting evidence suggests that NLR genes are important for the host response to 
pathogens and the regulation of inflammation.  Interest in these genes has been further 
propelled by the realization that mutations in certain NLR genes are linked to human 
autoinflammatory and immunodeficiency diseases.  For example, mutations in CIITA, the 
MHC class II transactivator, lead to a severe immunodeficiency disease, Bare Lymphocyte 
Syndrome (111).  Mutations in NOD2/CARD15 are associated with Crohn's disease and 
Blau syndrome, two human disorders with hyperinflammatory manifestations (30-32, 112).  
Finally,  mutations in the  Cold-Induced Autoinflammatory Syndrome-1 gene (CIAS1, also 
NALP3) is associated with a spectrum of autoinflammatory disorders which likely 
represent similar diseases with varying severity: Familial Cold-Induced Autoinflammatory 
Syndrome (FCAS), Muckle–Wells Syndrome (MWS) and Neonatal-Onset Multisystem 
Inflammatory Disease (NOMID)/Chronic Infantile Neurologic, Cutaneous, Articular 
Syndrome (CINCA) (29, 113-116). Most notably, the majority of known disease-
associated mutations within these NLR genes reside within the NBD domain.  However, 
the influence of these mutations on the nucleotide binding activity remains poorly 
understood.  
Several recent studies have provided greater detail regarding the mechanism and 
biological significance of nucleotide binding by NLR and NLR-related proteins.  
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Apoptotic protease activating factor-1 (APAF-1) is a protein that contains a central NBD 
and C-terminal WD-40 repeats and thus is closely related to the NLR family.  Under 
apoptotic conditions, APAF-1 binds cytochrome C.  This interaction stimulates APAF-1 
binding to dATP leading to the formation of an APAF-1 heptamer that activates caspase-9.  
Thus dATP binding by APAF-1 is a key regulatory step in the apoptotic process (106, 117).  
Similar to APAF-1, the NLR protein NLRP3 (previously known as cryopyrin, CIAS1 or 
NALP3) also requires nucleotide binding for its activity.  Our group has recently 
demonstrated that, in the absence of a functional NBD, NLRP3 cannot form an active 
inflammasome.  This results in reduced IL-1β processing and decreased cell death (118). 
Most importantly, inactivation of the NBD of NLRP3 abolishes the hyper-reactive 
phenotype of naturally occurring disease-associated mutations of this NLR protein.  This 
demonstrates that nucleotide binding is required for the inflammatory phenotype of 
NLRP3 linked diseases.         
In light of these findings, we examined the contribution of nucleotide binding to the 
functional role of an NLR protein, Monarch-1/NLRP12.  Monarch-1 is expressed 
predominantly in cells of the myeloid lineage, including monocytes and granulocytes  
Furthermore, single nucleotide polymorphism analysis has recently demonstrated a genetic 
link between Monarch-1 and atopic dermatitis (91).  However, in contrast to most NLR 
proteins that promote inflammation, Monarch-1 functions as an attenuator of inflammatory 
responses.  Monarch-1 inhibits TLR-mediated hyperphosphorylation of IRAK-1, a 
necessary step in IRAK-1 signaling pathways (92).  In addition, Monarch-1 binds to and 
destabilizes the MAP3 kinase, NF-κB inducing kinase (NIK) and blocks NIK-mediated 
processing of NF-κB2/p100 to p52.  The p52 subunit is an important downstream mediator 
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of signaling by TLRs as well as TNF family receptors including CD40 and lymphotoxin-
beta receptor.  The introduction of shRNA specific for Monarch-1 greatly enhances NF-κB 
activation and the transcription of NIK-dependent genes induced by TLR and/or TNF 
family receptor activation (93).  These earlier studies suggest that Monarch-1 performs an 
important anti-inflammatory role as an inhibitory molecule of innate immune activation. 
In this report, we explore the role of nucleotide binding in the anti-inflammatory 
activity of Monarch-1.  Herein, we demonstrate that Monarch-1, purified to homogeneity, 
specifically binds ATP.  Nucleotide binding is indispensable for the biological function of 
Monarch-1, as an NBD mutant form of Monarch-1 does not inhibit IRAK-1 
hyperphosphorylation nor does it inhibit NIK-dependent p52 production.  Moreover, THP-
1 monocytes stably expressing the NBD mutant form of Monarch-1 secrete elevated levels 
of proinflammatory cytokines and chemokines.  These results open the door for the 
characterization of the nucleotide binding properties of other NLR members and will 
facilitate the design of pharmacological agents that modulate the functions of this family of 
proteins. 
2.2 Materials and Methods 
2.2.1 Reagents  
The TLR2 agonist, the synthetic lipoprotein S-[2,3-bis-(palmitoyloxy)-2(2-RS)-
propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH trihydrochloride (Pam3Cys4) was 
obtained from Invivogen. CD40L was obtained from PeproTech.  Anti-His-HRP 
conjugates were obtained from (Santa Cruz) and anti-Flag M2-HRP was obtained from 
Sigma.  THP-1 cell lines stably expressing empty vector (THP-EV), Ha-tagged WT 
Monarch-1 (THP-WT) or shRNA targeting Monarch-1 (THP-shMon) have been described 
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(92, 93). The THP-1 cell line stably expressing Ha-tagged Monarch-1 containing the 
Walker A/B mutation was generated by the same procedure (THP-mutA/B). 
2.2.2 Expression and purification of bacterial      MBP-Monarch-1-NBD 
fusion protein   
The cDNA sequence encoding amino acids 188-448 of Monarch-1 that includes the 
Walker A/B motifs was amplified by PCR using PFU Turbo polymerase (Stratagene). 
Restriction enzyme sites for HindIII and BamHI were incorporated into the 5’ and 3’ end 
of PCR product respectively. DNA sequence encoding a 6xHis tag was also introduced in 
the 3’ reverse primer. The amplified product was digested by HindIII and BamHI (New 
England Biolabs) and cloned into the C-terminus of the maltose binding protein (MBP) in 
the vector pMAl-c2E (New England Biolabs).  Mutations in both Walker A and Walker B 
were generated by site-direct mutagenesis (Stratagene).  All constructs were confirmed by 
DNA sequencing.  The MBP-Monarch-1-NBD fusion plasmids were transformed into the 
Escherichia coli strain Rossetta-Origami B (EMB bioscience).  One liter of LB with 100 
μg/ml ampicillin was inoculated with 5 ml overnight bacteria culture.  The culture was 
grown at 37 °C to a density of OD600 = 0.8 and then isopropylthio-β-galactoside (IPTG) 
was added to a final concentration of 0.3 mM to induce the expression of the MBP fusion 
proteins. After 3 hr of induction at 25 °C, the cells were harvested by centrifugation at 
6000 rpm.  Cell pellets were washed once with cold PBS and resuspended in ice cold lysis 
buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 10 mM β-ME and Roche 
protease inhibitor cocktail).  Resuspension was facilitated by sonication for 2 min.  
Bacteria were then lysed with recombinant lysozyme (EMB bioscience) followed by 
benzonase (EMB Bioscience) treatment to degrade bacterial DNA and RNA.  Bacterial 
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lysates were clarified by centrifugation twice at 15,000 g for 30 min. The supernatant was 
filtered through a 0.2 µm low-protein binding filter.  Amylose resin (New England Biolabs) 
was washed twice with column buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10 
mM β-ME) and added directly to the bacterial lysate. The lysate/resin mix was rotated at 4 
°C for 1 hr and then transferred into an empty column. The resin was washed with 10 
volumes of column buffer and eluted with five volumes of column buffer containing 10 
mM maltose.  The eluate containing MBP fusion protein was concentrated with Amicon 
centrifugal filter device.  The partially purified MBP-Monarch-1-NBD fusion proteins 
were further purified over an FPLC size-exclusion column (Biosilect 400, Bio-Rad).  Each 
fraction was tested for nucleotide binding activity.  The fractions with high nucleotide 
binding activity were pooled and subsequently purified on a cobalt based metal affinity 
column (Sigma) and eluted with 300 mM imidazole. 
2.2.3 Expression and purification of mammalian cell-derived Monarch-
1ΔLRR. 
cDNA encoding Monarch-1 amino acids 1-686, which correspond to the pyrin and 
NBD domain, was PCR amplified and cloned into the pCEP4 vector (Invitrogen) by 
standard molecular cloning procedures.  This expression construct was introduced into the 
HEK293EBNA cell line (ATCC CRL10852) using polyethyleneimine (PEI; Polyscience).  
The transfected HEK293EBNA cells were then harvested and lysed in hypotonic lysis 
buffer (25 mM Hepes/KOH, pH7.5, 10 mM KCl , 5 mM MgCl2, 0.1mM PMSF and Roche 
protease inhibitor cocktail) for 15 min on ice followed by a brief sonication for 40 seconds.  
Lysates were cleared by centrifugation at 20,000 rpm for 30 min and filtered through 0.45 
μm filter. The lysate was then subject to cobalt metal affinity resin purification (Clontech).  
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The eluate was further purified over an anti-Flag affinity matrix and eluted with excess 
Flag peptide (Sigma).  These eluates were resolved by SDS-PAGE and proteins visualized 
with Coomassie blue stain. 
2.2.4 Nucleotide binding assay 
A rapid filter binding assay was developed to measure nucleotide binding to 
Monarch-1 fusion proteins.  [γ-35S]ATP (1250 Ci/mmole) (Perkin Elmer Life and 
Analytical Sciences) was mixed with the indicated amount of recombinant Monarch-1 in a 
final volume of 100 µl of binding buffer (50 mM TrisHCl, 150 mM NaCl, 20mM MgCl2, 
2mM DTT, 5% Glycerol, pH 7.5) and was incubated at 30°C  for 1hr.  After this 
incubation, the samples were filtered through a 96-well nitrocellulose plate (Millipore) and 
immediately washed twice with 200 µl of ice-cold binding buffer by vacuum filtration 
(Millipore).  The filter plate was then air-dried and radioactivity was measured using a 
scintillation counter.  For homologous competition assays, Monarch-1-NBD fusion protein 
(2 μg) or Monarch-1ΔLRR (450 ng) was incubated with 90 nM [γ-35S] ATP and increasing 
concentrations of unlabeled [γ-S]ATP.  Curves represent non-linear regression fit to single 
site completion model.  Nucleotide binding specificity was determined by incubating 
Monarch-1-NBD fusion protein with [γ-32S] ATP and 10 μM of the indicated unlabeled 
competitor nucleotide. 
2.2.5 ATPase assay 
ATP hydrolysis was measured by visualizing the conversion of 32P-ATP to 32P-
ADP using thin layer chromatography.  5 μg of purified Monarch-1ΔLRR was incubated 
with 10 μM ATP and 0.1 μM 32P-ATP (3000 Ci/mmol, Perkin Elmer life and Analytical 
Science) in a total volume of 40 μl reaction buffer (25 mM TrisHCl, pH7.5, 150 mM NaCl, 
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10 mM MgCl2, 1 mM DTT, 1 mM EDTA, 0.1 mM PMSF) for 2 hours.  The reaction was 
quenched by adding an equal volume of TLC development solvent (1 M formic acid, 0.5 
M LiCl).  2 μl of the reaction was spotted on a PEI cellulose TLC plate (Sigma) and 
developed with 1 M formic acid with 0.5 M LiCl in a TLC chamber.  The TLC plate was 
then exposed to X-ray film. 
2.2.6 ELISA 
THP-1 derived cell lines were stimulated with conditions indicated.  Cytokine and 
chemokine levels in cell supernatants were analyzed by sandwich ELISA using antibody 
pairs and protocols as recommended (R&D systems). 
2.2.7 Immunoprecipitation and western blot analysis 
HEK293T and THP-1 cell lines, stimulated with conditions indicated, were lysed in 
buffer containing 1% Triton X-100,150 mM NaCl, 50 mM Tris-HCl (pH 8), 50 mM NaF, 
2 mM EDTA, plus a protease inhibitor cocktail (Roche). Immunoprecipitates were washed 
four times in lysis buffer and eluted by boiling in reducing sample buffer. Samples were 
fractionated by SDS-PAGE and transferred to nitrocellulose. Western blots were probed 
with the indicated antibodies then visualized by enhanced chemiluminescence (Pierce) and 
exposure to photographic film (Genesee Scientific). The films were scanned into Adobe 
Photoshop and whole images were adjusted for brightness. The images were cropped and 
formatted in Adobe Illustrator. Nuclear/cytoplasmic fractions were prepared using the 
Pierce NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit. The following 
antibodies were used: anti-Ha 12CA5 (Roche), anti-IRAK-1 (C-20), anti-NIK (H-248), 
anti-CagA (b-300, isotype control) (Santa Cruz Biotechnology). 
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2.3 Results 
2.3.1 Enrichment and characterization of recombinant Monarch-1 
Initial attempts to express full-length Monarch-1 protein using Escherichia coli and 
baculovirus expression systems failed to yield a sufficient quantity of soluble protein for 
biochemical analysis despite extensive testing and optimization of expression conditions 
and parameters.  This is a common problem encountered in the study of this family of 
proteins (119).  Therefore, to improve solubility, we employed a maltose binding protein 
(MBP) expression system, in which MBP was fused to the NBD of Monarch-1. 
The NBD can be divided into a NACHT domain (NAIP, CIITA, HET-E and TP1) 
(14) and NACHT-associated domains (NAD) (120).  The NACHT domain of NLR 
proteins contains well conserved nucleotide binding structures including the ATP/GTP-
specific phosphate binding loop called Walker A and an Mg2+ coordination site called 
Walker B (95, 121, 122).  We generated a fusion protein containing MBP fused to amino 
acids 188-448 of Monarch-1 (Figure 2-1A). In addition to the N-terminal MBP moiety, a 
6xHis tag was added to the C-terminus of the Monarch-1-NBD fusion proteins to facilitate 
purification by dual-affinity chromatography.  The aa188-448 region of Monarch-1 
comprises the NACHT domain, NAD1.  We predicted this region to have nucleotide 
binding properties based upon: 1) the crystal structure of the related dATP binding protein 
Apaf-1 and, 2) a recent molecular modeling study in which the previous broadly defined 
NBD domain was subdivided to the NACHT domain and three subsequent NAD 
sequences (120). 
NACHT domains consist of six α-helices and β-sheet core structure, which contains 
the highly conserved Walker A and Walker B motifs responsible for nucleotide binding.  
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The Walker A motif contains the consensus sequence GxxGxGK[T/S], wherein the 
conserved lysine residue is responsible for coordination of the α and β-phosphate moieties 
of ATP.  The Walker B motif, DxxDE, contains two well-conserved aspartic acid residues; 
the first of which is involved in coordination of Mg2+ and the second aspartic acid and the 
third glutamate are involved ATP hydrolysis.  To ensure complete disruption of nucleotide 
binding, mutations were introduced within both the Walker A and Walker B motifs and 
will be referred to hereafter as mutA/B. 
Plasmids encoding the wild type (WT) or mutA/B Monarch-1-NBD fusion proteins 
were transformed into E. coli and were predominantly expressed as soluble proteins of 
approximately 80 kDa (Figure 2-1B).  An affinity based amylose resin targeting MBP was 
used to enrich the fusion proteins and yielded a partially purified product (Figure 2-1C).  
Although MBP increases the solubility of its cargo protein, a large portion of the fusion 
protein may remain in a misfolded, high molecular weight soluble aggregate that is 
biochemically inactive. To separate functionally active protein from these soluble 
aggregates and further purify the protein, we applied the amylose resin-enriched product to 
a size exclusion column. Figure 2-1D depicts the FPLC elution profile of WT Monarch-1-
NBD and the Coomassie blue stained SDS-PAGE gel containing the size exclusion 
fractions.  The mutA/B Monarch-1-NBD fusion protein exhibited identical expression and 
chromatographic profile as the WT protein (data not shown).  A large percentage of the 
protein (70-80%) eluted in fractions 12-14.  These fractions consisted of the excluding 
volume of column (>700 kDa) and represent proteins existing in a high molecular weight 
aggregation state.  Fractions 15-19 contained the Monarch-1-NBD fusion protein existing 
in lower molecular weight states (~80-300 kDa), which likely represented monomeric, 
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dimeric and trimeric complexes.  Fractions 20-22 contained degradative products (Figure 
2-1D).  The presence of intact Monarch-1-NBD was confirmed by Western blot analysis of 
fractions 17-21 using antibodies against N-terminal MBP and C-terminus 6xHis (Figure 
2-1E).  The MBP antibody detected full-length Monarch-1-NBD protein as well as smaller 
molecular weight moieties.  The anti-6XHis antibody only detected full-length Monarch-1-
NBD proteins.  This suggests that the smaller moieties detected by the MBP antibody in 
fractions 20-21 were likely MBP fusion proteins missing an intact C-terminus. 
To determine if the gel filtration fractions contained biochemically active Monarch-
1-NBD, an ATP binding assay was performed. In this assay, recombinant proteins from 
each fraction were incubated with radio-labeled [γ-35S]ATP, a nonhydrolysable ATP 
analog, and then loaded onto a nitrocellulose filter plate.  Protein-bound nucleotides were 
trapped on the membrane while free nucleotides passed through the membrane by repeated 
buffer washes.  Fractions 12-14, corresponding to the high molecular weight aggregates, 
exhibited poor ATP binding activity (Figure 2-1F).  This suggests that these high 
molecular weight soluble aggregates of Monarch-1-NBD likely remained in a misfolded, 
inactive state.  In contrast, ATP binding activity significantly increased in the smaller 
molecular weight fractions, with fractions 18 and 19 exhibiting the highest ATP binding 
activity.  To assess if the Walker A and B motifs are required for nucleotide-binding, we 
performed this ATP binding assay using size exclusion chromatography fractions 
containing mutA/B Monarch-1-NBD.  Mutations within the Walker A/B sequences 
dramatically reduced the nucleotide binding activity of the protein (Figure 2-1F), 
demonstrating their importance for Monarch-1 nucleotide binding.  The greatest difference 
was observed in fraction 19, where the ATP-binding activity of WT Monarch-1-NBD was 
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5-fold higher than the corresponding mutA/B form of the protein.  Together these results 
indicate that Monarch-1 binds ATP, and the Walker A/B motifs are required for nucleotide 
binding. 
2.3.2 Monarch-1 specifically binds ATP. 
To more accurately determine both the affinity and specificity of ATP binding, we 
further purified WT Monarch-1-NBD by taking advantage of the C-terminal 6xHis tag.  
Fractions 18 and 19, which demonstrated the highest level of nucleotide binding (Figure 
2-1F), were pooled and applied to a cobalt-based, metal affinity purification column.  The 
resulting product was highly enriched and migrated as a single band at ~80kDa as 
examined by Coomassie blue staining (Figure 2-2A).  To determine the affinity of ATP 
binding, highly enriched WT Monarch-1-NBD was incubated with radio-labeled [γ-
35S]ATP along with increasing concentrations of unlabeled [γ-S]ATP. The dissociation 
constant (Kd) of [γ-35S]ATP binding was determined to be 100 nM (Figure 2-2B).  Next 
we tested the nucleotide binding preference of WT Monarch-1-NBD.  The fusion protein 
was preincubated with radio-labeled ATPγS for 2 hr and then unlabeled [γ-S]ATP, ATP, 
GTP, or CTP was added to compete for WT Monarch-1-NBD binding.  Unlabeled [γ-
S]ATP and ATP displaced radio-labeled [γ-35S]ATP, while CTP and GTP had no such 
effect, demonstrating that WT-Monarch-1-NBD specifically binds ATP (Figure 2-2C). 
2.3.3 Recombinant Monarch-1 derived from mammalian cells binds ATP. 
The experiments described above employed WT Monarch-1-NBD fusion proteins 
derived from bacteria to demonstrate ATP binding activity.  However, these fusion 
proteins lacked the N-terminal Pyrin domain and C-terminal LRR domain found in the full 
length protein.  The crystal structure of Apaf-1 indicates that its N-terminal effector 
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domain folds back on the ATP binding pocket within the NBD (107).  Although this does 
not affect dATP binding by Apaf-1, this observation led us to question if the Pyrin or LRR 
domains of Monarch-1 affect nucleotide binding. 
To determine the influence of these domains on ATP binding activity, we purified 
full length Monarch-1 using a mammalian expression system.  In order to enhance protein 
expression, we employed an Epstein - Barr virus (EBV) based episomal replication system.  
Sequences encoding WT and mutA/B Monarch-1 were cloned into EBV expression 
vectors and an N-terminal 10xHis tag and a C-terminal Flag tag were added to facilitate 
dual-affinity purification.  Again, we were unable to obtain sufficient quantities of full 
length Monarch-1.  However, soluble Monarch-1 protein was successfully obtained after 
deleting the LRR domain (Monarch-1ΔLRR) (Figure 2-3A).  WT and mutA/B Monarch-
1ΔLRR were first partially purified by cobalt metal affinity.  The recombinant proteins in 
this eluate were then further purified by anti-Flag affinity chromatography.  Coomassie 
blue staining along with anti-His and anti-Flag western blotting revealed a single band that 
corresponded to purified WT and mutA/B Monarch-1ΔLRR (Figure 2-3B and C). 
To determine if Monarch-1ΔLRR exhibited nucleotide binding activity, an ATP 
binding assay was performed.  As seen in the bacterial expression system, purified WT 
Monarch-lΔLRR exhibited strong ATP binding activity while this binding activity was 
dramatically reduced in the mutA/B form of the protein (Figure 2-3D).  Nucleotide 
competition assays determined the binding affinity to be 84 nM (Figure 2-3E).  This was 
comparable to the binding affinity observed with the WT Monarch-1-NBD fusion protein 
derived from bacterial expression.  In addition, similar to the bacterial-derived WT 
Monarch-1-NBD fusion protein, unlabeled ATP successfully competed for [γ-35S]ATP 
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binding while unlabeled CTP and GTP failed to do so even at 100 fold higher 
concentrations. 
2.3.4  Recombinant Monarch-1 derived from mammalian cells possesses 
ATPase activity. 
To determine if WT Monarch-1ΔLRR possessed ATP hydrolysis activity, the 
purified protein was incubated with radio-labeled 32P-ATP and the reaction mixture was 
analyzed by thin layer chromatography.  Whole cell lysate was used as a positive control to 
show the conversion of radio-labeled ATP to ADP, while bovine serum albumin, a non-
ATPase, was used as a negative control.  Purified WT Monarch-ΔLRR exhibited ATPase 
activity as shown by the conversion of ATP to ADP (Figure 2-3G).  Together, these results 
clearly demonstrate that Monarch-1 binds ATP and possesses ATPase activity. 
2.3.5 Nucleotide binding regulates Monarch-1 self-association.   
The oligomerization of NLR proteins has been shown to be important for their 
activity (117, 123) .  To determine if nucleotide binding is required for Monarch-1 self-
association, full-length forms of WT or mutA/B Monarch-1 were co-transfected into 
HEK293T cells.  Protein complexes were immunoprecipitated with anti-Flag antibody and 
Western blots probed with anti-Ha antibody to detect homomeric Monarch-1 complexes.  
As expected, WT Monarch-1 exhibited self-association (Figure 2-4 lane 3).  In addition, 
WT Monarch-1 also associated with mutA/B Monarch-1.  However, mutA/B Monarch-1 
failed to associate with another mutA/B molecule.  This suggests that complex formation 
among Monarch-1 molecules requires nucleotide binding, but that not every member of the 
complex must bind nucleotide.  This phenomenon was also observed for the NLR protein, 
CIITA, suggesting it may be a common feature of NLR proteins (123). 
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2.3.6 Nucleotide binding regulates the ability of Monarch-1 to inhibit NIK 
activity. 
Recently, we demonstrated that Monarch-1 suppresses activation of non-canonical 
NF-κB by associating with NF-κB inducing kinase, NIK. To determine the role of 
nucleotide binding in the formation of this molecular complex, HEK293 cells were co-
transfected with NIK and full length forms of Ha-tagged WT or mutA/B Monarch-1.  Cell 
lysates were immunoprecipitated with anti-NIK antibodies and Western blots were probed 
with anti-Ha antibody to detect Monarch-1.  As previously reported, WT Monarch-1 co-
precipitated with NIK (Figure 2-5A).  Similarly, mutA/B Monarch-1 also associated with 
NIK, suggesting that nucleotide binding is not a requirement for complex formation in this 
overexpression model.  To further assess the role of nucleothide binding in Monarch-NIK 
complex formation, THP-1 monocytes stably expressing Ha-tagged WT or mutA/B 
Monarch-1 were treated with CD40L to induce activation of endogenous NIK.  Cell 
extracts were immunoprecipitated with anti-NIK antibodies and Western blots were 
performed to detect co-precipitating Monarch-1.  As previously described, CD40L 
treatment enhanced the association of WT Monarch-1 with endogenous NIK (Figure 2-5B).  
In contrast, the association between mutA/B Monarch-1 and NIK failed to increase upon 
activation.  Thus, while nucleotide binding is not an absolute requirement for NIK binding, 
it is required for activation-induced complex formation. 
NIK activates noncanonical NF-kB by inducing proteolytic processing of NF-
κB2/p100 to p52.  This smaller active form of NF-κB2 rapidly translocates to the nucleus 
to regulate transcription of inflammatory genes.  In contrast, the unprocessed form, p100, 
functions as an inhibitor of NF-κB activity (124). We recently demonstrated that the 
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association of Monarch-1 with NIK results in suppression of p100 processing.  To 
determine the role of nucleotide binding in this function, THP-1 monocytes expressing an 
empty vector, WT Monarch-1 or mutA/B Monarch-1 were stimulated via TLR2 to induce 
p100 expression.  The cells were then treated with CD40L to induce NIK-dependent p100 
processing.  As previously reported, WT Monarch-1 suppressed p100 processing as 
demonstrated by a sharp reduction in nuclear p52 in THP-WT Monarch-1 cells (Figure 
2-5C, lane 4).  Moreover, this reduction in nuclear p52 occurred in the presence of elevated 
levels of cytoplasmic p100 in these cells.  Finally, the accumulation of p100 in the nucleus 
was consistently detected in THP-WT Monarch-1 cells, further emphasizing the role of 
Monarch-1 in inhibiting p100 processing.  In contrast to WT Monarch-1, mutA/B 
Monarch-1 did not affect CD40L induced activation of noncanonical NF-κB, as nuclear 
p52 levels were comparable to those seen in control THP-EV cells.  Thus, consistent with 
the inability of mutA/B Monarch-1 to bind NIK following activation, the NBD mutant did 
not inhibit p100 processing.  These results demonstrate that nucleotide binding is required 
for Monarch-1 to suppress noncanonical NF-κB. 
2.3.7 Nucleotide binding regulates the ability of Monarch-1 to inhibit 
IRAK-1 activation. 
In addition to NIK, we have also shown that upon TLR stimulation, Monarch-1 
binds IRAK-1 and inhibits its hyperphosphorylation (92).  To determine if nucleotide 
binding is required for the association of Monarch-1 with IRAK-1, THP-1 cells expressing 
WT or mutA/B Monarch-1 were stimulated with the TLR2 agonist, Pam3Cys4.  
Endogenous IRAK-1 complexes were captured by immunoprecipitation and Western blots 
performed to detect Monarch-1.  In agreement with our previous findings, complex 
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formation between WT Monarch-1 and IRAK-1 strengthened upon TLR stimulation 
(Figure 2-6A).  However, similar to NIK, mutA/B Monarch-1 associated more strongly 
with IRAK-1 in resting cells, and activation-induced association was abrogated by Walker 
A/B mutations.  Accordingly, TLR2 stimulation resulted in the hyperphosphorylation of 
IRAK-1 in THP-mutA/B Monarch-1 at levels comparable to control THP-EV cells (Figure 
2-6B).  In agreement with our previous findings, WT Monarch-1 suppressed the 
accumulation of these hyperphosphorylated forms of IRAK-1 (Figure 2-6B) (93).  These 
data confirm the requirement for nucleotide binding in Monarch-1 mediated suppression of 
inflammatory signaling. 
2.3.8 Nucleotide binding regulates the anti-inflammatory activity of 
Monarch-1. 
Previously, we demonstrated that Monarch-1 suppresses the production of 
proinflammatory cytokines and chemokines in stimulated monocytic cells (92, 93).  To 
determine the role of nucleotide binding in this anti-inflammatory activity, THP-1 cells 
stably expressing full length WT or mutA/B Monarch-1 were stimulated and supernatants 
were applied to a    cytokine antibody array (data not shown).  THP-1 cells stably 
transfected with empty vector (THP-EV) were used as controls.  In agreement with our 
previous reports, THP-1 cells expressing WT Monarch-1 produced lower levels of 
inflammatory cytokines and chemokines as compared to THP-EV control samples.  These 
included IL-6, CXCL12 and CXCL13, which have been previously shown to be 
suppressed by WT Monarch-1 (92, 93).  In contrast, THP-1 monocytes expressing mutA/B 
Monarch-1 produced increased levels of cytokines and chemokines as compared to control 
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samples.  Of the 79 cytokines/chemokines examined, we found the greatest differences in 
IL-6, CXCL6, and CXCL13 and these values are reported in Figure 2-7A.   
To confirm the results from the array, we performed ELISA experiments.  In these 
experiments, THP-1 cells expressing shRNA targeting endogenous Monarch-1 (THP-
shMon) were incorporated into the experiments.  As expected, the expression of WT 
Monarch-1 resulted in decreased production of IL-6, CXCL13, and CXCL6 as compared 
to THP-EV cells (Figure 2-7B).  In contrast, elevated levels of these cytokines/chemokines 
were detected in supernatants from THP-shMon cells, confirming our earlier reports 
demonstrating that silencing endogenous Monarch-1 results in a hyper-inflammatory 
response (92, 93).  Similar to THP-shMon cells, THP-mutA/B Monarch-1 cells also 
produced increased levels of these inflammatory mediators.  These results demonstrate that 
nucleotide binding is required for the anti-inflammatory activity of Monarch-1.  In addition, 
these results suggest that the presence of a nucleotide binding deficient form of Monarch-1 
can block the activity of endogenous Monarch-1. 
2.4 Discussion 
Despite the general perception that members of the NLR family function as 
nucleotide-binding proteins, this property has not been extensively studied.  Among plant 
R proteins, one group has shown data derived from R proteins that demonstrate nucleotide 
binding properties of these proteins (108).  Furthermore, despite this lack of convincing 
data, the assumption has been that nucleotide binding is required for the function of these 
proteins.  This concept is largely modeled after the analysis of Apaf-1 (125).  Thus, a key 
finding in this report is that highly enriched Monarch-1 specifically binds ATP and this is 
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required for its anti-inflammatory activity.  Monarch-1 is also unique in that it functions as 
a brake of innate immune activation, as opposed to several of the other NLR proteins. 
The requirement of nucleotide binding for Monarch-1 activity supports a recent 
report by our group that focused on the NLR protein, cryopyrin/NLRP3.  In that report, we 
demonstrated that NLRP3 binds ATP and this binding activity is required for NLRP3-
mediated IL-1β processing (118).   Prior to these studies, only two other reports suggested 
nucleotide binding as a regulatory step in NLR function.  An earlier report from our group 
suggested that CIITA binds GTP and mutations within the Walker A/B motifs block 
CIITA-mediated transcriptional activation (110).  In that study, however, nucleotide 
binding assays were performed by analyzing CIITA proteins that had been 
immunoprecipitated from transfected cells.  Since CIITA forms large protein complexes, 
the nucleotide binding activities of co-precipitating proteins could not be ruled out.  More 
recently, GST-fusion proteins containing the NBD of the NLR protein Ipaf were shown to 
bind ATP (119).  Mutations with the Walker A motif of Ipaf result in reduced caspase-1 
activity.  However, similar to the CIITA study, protein purity remains an issue in this study.   
In this report, we produced highly enriched Monarch-1 fusion proteins derived 
from both prokaryotic and eukaryotic expression systems to conclusively demonstrate the 
nucleotide binding activity of Monarch-1.  The importance of Monarch-1 nucleotide 
binding in suppressing NF-κB activation and inflammatory signaling has been clearly 
demonstrated in this report.  Expression of a nucleotide binding deficient form of 
Monarch-1 (mutA/B Monarch-1) in monocytes resulted in dramatically increased 
production of proinflammatory mediators.  These levels were comparable to those 
observed in THP-shMon cells in which endogenous Monarch-1 expression was silenced.  
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This hyper-inflammatory phenotype of cells expressing mutA/B Monarch-1 correlates well 
with the inability of this mutant to suppress NF-κB2/p100 processing and the inability of 
this mutant to efficiently bind NIK and IRAK-1 following stimulation. 
Interestingly, an association was detected between these kinases and mutA/B 
Monarch-1 in resting cells.  This suggests that the mutations within the Walker A/B 
sequences are subtle enough not to disrupt complex formation in resting cells but render 
Monarch-1 unable to bind these kinases upon stimulation.  This loss of activation-induced 
NIK and IRAK-1 binding by mutA/B Monarch-1 may be due to its inability to form 
homomeric structures, a property required for the activity of CIITA, APAF-1 and NALP3.  
A second possibility relates to the functional dissection of ATP binding and ATP 
hydrolysis.  For instance, it has been reported that ATP binding is required for the activity 
of the plant R protein I-2, yet the hydrolysis of this bound ATP moiety suppresses I-2 
function (108, 109).  Thus, binding and hydrolysis ATP may represent an on/off switch of 
NLR protein function.  Future studies will be conducted to fully characterize the ATP 
hydrolysis cycle of Monarch-1 and to determine its contribution to the anti-inflammatory 
role of Monarch-1. 
Despite exhaustive attempts to optimize conditions, we were not able to produce 
sufficient quantities of soluble, full-length purified protein.  Instead, we generated 
recombinant Monarch-1 in mammalian cells by deleting the LRR domain.  Thus, while it 
is clear that Monarch-1 binds ATP, it remains uncertain whether the LRR domain regulates 
this activity.  In our recent report describing ATP binding by cryopyrin, purified proteins 
contained intact LRR sequences, and these domains did not affect ATP binding.  Therefore, 
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due to the sequence similarities between Monarch-1 and NALP3, it is unlikely that the 
LRR domain disrupts nucleotide binding. 
 The nucleotide binding property of NLRs lends these proteins to pharmacologic 
intervention, as there are abundant nucleotide and nucleoside analog libraries available for 
drug screening.  Thus, the possibility now emerges to screen for nucleotide analogs that 
can bind to Monarch-1, cause sustained blockage of its function, and potentiate innate 
immune responses.  In summary, our work demonstrates that Monarch-1 is an ATP 
binding protein and this ATP binding activity is essential for Monarch-1 to perform its 
inhibitory role in innate immune signal. 
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Figure 2-1 The generation and purification of Monarch-1 –NBD fusion proteins 
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Figure 2-1 The generation and purification of Monarch-1-NBD fusion proteins.  (A) 
Schematic diagram of domain structure of full length Monarch-1 and the WT and mutA/B 
Monarch-1-NBD fusion proteins. The positions of the Walker A and Walker B motifs are 
depicted as solid bars within the NACHT domain. The conserved amino acids within both 
motifs are shown and the underlined residues were substituted with alanine by site-directed 
mutagenesis.  (B) The pMAL-c2E vector encoding WT and mut A/B Monarch-1-NBD 
were transformed into E. coli strain Rosetta origami B.  Soluble bacterial extracts before 
and after IPTG induction were analyzed by SDS-PAGE and Coomassie blue staining. 
Arrowhead, Monarch-1-NBD fusion protein; U, uninduced; I, IPTG-induced.  (C) 
Bacterial lysates were passed over an amylose resin column targeting MBP.  Eluted 
proteins were resolved by SDS-PAGE and visualized with Coomassie blue stain.  (D) 
Eluates from the amylose resin column were further purified by size exclusion 
chromatography.  The absorbance profile of size exclusion purification is depicted (upper 
panel) and the size exclusion fractions were analyzed by SDS-PAGE and visualized by 
Coomassie blue staining (lower panel).  (E) Western blots from size exclusion fractions 
17-21 were probed with an anti-MBP antibody to verify the intactness of the N-terminus 
and anti-His to determine the intactness of the C-terminus of the Monarch-1-NBD fusion 
protein. (F) Size exclusion fraction from WT or mutA/B Monarch-1-NBD were tested for 
ATP binding activity using [γ-32S]ATP and specific binding was normalized to the protein 
concentration of each fraction. 
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Figure 2-2 Purified Monarch-1-NBD fusion protein specifically binds ATP 
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Figure 2-2 Purified Monarch-1-NBD fusion protein specifically binds ATP.  (A) Gel 
filtration fractions 18-19 (Fig.1) were pooled and further purified by cobalt metal affinity 
chromatography.  Eluates were concentrated and the buffer exchanged over a PD10 
column.  The purity of the final purification product was assessed by SDS-PAGE followed 
by visualization with Coomassie blue stain.  Arrowhead, Monarch-1-NBD fusion protein.  
(B) Homologous competition assays were performed to assess the ATP binding affinity of 
Monarch-1-NBD.  (C) Specificity of ATP binding was determined by incubating Monarch-
1-NBD fusion protein with [γ-32S] ATP and 10 μM of the indicated unlabeled competitor 
nucleotide. 
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Figure 2-3 Mammalian cell-derived recombinant Monarch-1ΔLRR binds and hydrolyzes ATP 
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Figure 2-3 Nucleotide binding is required for Monarch-1 to suppress NIK-mediated 
p100 processing.  (A) HEK293T cells were co-transfected with NIK and Ha-tagged WT or 
mutA/B Monarch-1.  Cell lysates were immunoprecipitated with anti-NIK antibodies and 
western blots probed with anti-Ha antibodies to detect Monarch-1.  (B) THP-WT or THP-
mutA/B cells were stimulated with 250 ng/ml CD40L for indicated times.  Endogenous 
NIK was immunoprecipitated with anti-NIK antibodies and western blots probed with anti-
Ha to detect co-precipitating Monarch-1.  Control immunoprecipitations were performed 
with an isotype control antibody to monitor specificity.  Control western blots were 
performed to monitor expression of Monarch-1 and NIK in cellular lysates.  (C) THP-EV, 
THP-WT or THP-mutA/B cells were stimulated with 200 ng/ml Pam3Cys4 for 18 h to 
induce p100 expression.  The cells were then treated with 250 ng/ml CD40L for an 
additional 5 h to induce p100 cleavage to p52.  Cells were fractionated into nuclear and 
cytoplasmic fractions and proteins from each fraction were separated by SDS-PAGE.  
Western blots were probed with anti-p100 to detect p100 and its cleaved form, p52.  Anti-
Ha was used to monitor Monarch-1 expression. 
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Figure 2-4 Nucleotiding binding is required for Monarch-1 self association. 
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Figure 2-4 Mammalian cell-derived recombinant Monarch-1ΔLRR binds and hydrolyzes 
ATP.  (A) Diagram depicting full length Monarch-1 and the WT and mutA/B Monarch-
1ΔLRR proteins produced in HEK293EBNA cells.  (B) Soluble extracts of HEK293EBNA 
cells expressing WT and mutA/B Monarch-1ΔLRR were enriched for Monarch-1ΔLRR 
using a cobalt metal affinity column.  Eluates were resolved by SDS-PAGE, and visualized 
with Coomassie blue staining (lanes 1-2).  The cobalt eluate was further purified over an 
anti-Flag affinity matrix and the purity was evaluated by Coomassie blue staining (lanes 3-
4).  (C) The double purified Monarch-1ΔLRR proteins were analyzed by western blot 
using anti-His antibody and anti-Flag antibody.  (D) ATP binding activity of purified WT 
and mutA/B Monarch-1ΔLRR was determined by incubating 500 ng purified protein with 
90 nM [γ-32S]ATP.  Error bars represent the standard deviation of ATP binding 
measurements in triplicate.  (E) The ATP binding affinity of WT-Monarch-1ΔLRR was 
determined by homologous competition binding assays.  (F) The nucleotide binding 
preference of WT-Monarch-1ΔLRR was determined by incubating WT-Monarch-1ΔLRR 
with [γ-32S]ATP and increasing concentrations of unlabeled nucleotide.  (G) The ATPase 
activity of purified WT-Monarch-1ΔLRR was measured by visualizing the conversion of 
32P-ATP to 32P-ADP by thin layer chromatography followed by autoradiography.  
HEK293EBNA lysate and purified bovine serum albumin (BSA) were used as positive and 
negative controls, respectively.  Arrowhead, Monarch-1-NBD fusion protein. 
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Figure 2-5 Nucleotide binding is required for Monarch-1 to suppress NIK-mediated p100 processing. 
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Figure 2-5 Nucleotide binding is required for Monarch-1 to suppress NIK-mediated p100 
processing.  (A) HEK293T cells were co-transfected with NIK and Ha-tagged WT or 
mutA/B Monarch-1.  Cell lysates were immunoprecipitated with anti-NIK antibodies and 
western blots probed with anti-Ha antibodies to detect Monarch-1.  (B) THP-WT or THP-
mutA/B cells were stimulated with 250 ng/ml CD40L for indicated times.  Endogenous 
NIK was immunoprecipitated with anti-NIK antibodies and western blots probed with anti-
Ha to detect co-precipitating Monarch-1.  Control immunoprecipitations were performed 
with an isotype control antibody to monitor specificity.  Control western blots were 
performed to monitor expression of Monarch-1 and NIK in cellular lysates.  (C) THP-EV, 
THP-WT or THP-mutA/B cells were stimulated with 200 ng/ml Pam3Cys4 for 18 h to 
induce p100 expression.  The cells were then treated with 250 ng/ml CD40L for an 
additional 5 h to induce p100 cleavage to p52.  Cells were fractionated into nuclear and 
cytoplasmic fractions and proteins from each fraction were separated by SDS-PAGE.  
Western blots were probed with anti-p100 to detect p100 and its cleaved form, p52.  Anti-
Ha was used to monitor Monarch-1 expression. 
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Figure 2-6 Nucleotide binding by Monarch-1 is required for the suppression of IRAK-1 
hyperphosphorylation. 
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Figure 2-6 Nucleotide binding by Monarch-1 is required for the suppression of IRAK-1 
hyperphosphorylation.  (A) THP-WT or THP-mutA/B cells were stimulated for the 
indicated times with 200 ng/ml Pam3Cys4.  Endogenous IRAK-1 was immunoprecipitated 
with anti-IRAK-1 antibodies and western blots were probed with anti-Ha to detect 
Monarch-1.  Control samples were immunoprecipitated with an isotype matched antibody.  
Control western blots were performed on cellular lysates to monitor the levels of Monarch-
1 and IRAK-1.  (B)  THP-EV, THP-WT and THP-mutA/B cells were stimulated with 200 
ng/ml Pam3Cys4 for the indicated times.Lysates were separated by SDS-PAGE and 
western blots probed with anti-IRAK-1 antibodies.  Control western blots were performed 
and probed with anti-Ha to monitor Monarch-1 expression 
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Figure 2-7  Nucleotide binding is required for Monarch-1-mediated suppression of proinflammatory 
cytokine and chemokine production. 
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Figure 2-7 Nucleotide binding is required for Monarch-1-mediated suppression of 
proinflammatory cytokine and chemokine production.  (A)  THP-1 cells expressing empty 
vector (EV), full length WT Monarch-1 (WT) or full length mutA/B Monarch-1 (mutA/B) 
were stimulated with 200ng/ml Pam3Cys4 for 18 h and then 250 ng/ml CD40L for an 
additional 5 h.  Supernatants were applied to a RayBiotech cytokine/chemokine array.  The 
values for the three cytokines/chemokines that demonstrated the most dramatic differences 
among the cell lines are shown as fold induction over unstimulated samples.  (B) THP-EV, 
THP-WT, THP-mutA/B and THP-shMon were stimulated as described above.  Cell culture 
supernatants were harvested and cytokine/chemokine levels determined by ELISA. 
Chapter 3 Investigating the role of conserved NBD motifs in 
mediating Monarch-1 function 
Abstract 
 The recently discovered Nucleotide Binding Domain-Leucine Rich Repeat (NLR) 
gene family has emerged as key player in the induction and modulation of the innate 
immune response.  This family is defined by a central nucleotide binding domain that 
contains 9-12 conserved motifs including Walker A and Walk B, which has been 
demonstrated to play a vital role in mediating nucleotide binding activity. In the previous 
chapter, I examined the nucleotide binding property and its biological function in NLR 
protein, Monarch-1. In this chapter, I sought to determine the biological function of the 
remaining conserved regions within the NBD domain of Monarch-1. Nine THP-1 cell lines 
stably expressing WT and Monarch-1 conserved NBD domain mutants have been 
established and their negative regulatory role of cytokine/chemokine secretion has been 
examined.  Among all conserved motifs, Walker A (motif 1), Walker B (motif 2), Motif 6 
and Motif 9 have been identified to play a critical role in meditating the negative regulating 
cytokine/chemokine IL-6, BLC and GCP-2. This result further highlights the role of 
nucleotide binding in the in vivo function of Monarch-1 and reveals novel functional 
motifs in the NBD domain of NLR proteins. 
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3.1 Introduction 
The newly discovered NLR protein family is critically involved in mediating 
inflammatory response against a variety of pathogens (7, 8). A number of NLRs function as 
intracellular PAMP sensor. Upon directly or indirectly engagement by their cognate agonists, 
NLRs swiftly activate NF-κB signaling pathway leading to the secretion of proinflammatory 
cytokines such as TNF-α and IL-6. The activation of some NLRs results in the formation of a 
multiprotein complex called 'inflammasome' (47), which eventually leads to the activation of 
caspase-1 and IL-1β and IL-18 secretion. The activation of NLRs also elicits a host cell death 
program manifested by either pathogen induced apoptosis or necrosis. Finally, a group of 
NLR proteins have negative regulatory roles in the control of inflammatory molecules such 
as chemokines and interferons. 
One of the hallmarks of the NLRs is the central localized nucleotide binding domain 
that is also named as NACHT (14) or NOD domain. The NBD domain itself is highly 
homologous to an ancient AAA+ ATPase family, which has been shown to exert diverse 
biological functions (94). The major mechanism by which the AAA+ ATPase functions is its 
oligomerization upon ATP binding and hydrolysis. However, the precise biochemical action 
steps from ATP binding/hydrolysis to oligomerization have not been fully characterized (97). 
Given sequence similarity between NLR protein and AAA+ ATPase family, the NLRs 
have been presumed to bind/hydrolyze nucleotide since the indetification of its first family 
member, CIITA. However, the definitive biochemical proof of nucleotide binding of NLR 
family has only recently provided by our group and others (118, 119). The nucleotide binding 
of NLR protein is predicated to result in a conformational change that eventually leads to the 
oligomerization of the protein. This notion is largely modeled on the mechanism of Apaf-1 
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mediated Apoptosome formation. Apaf-1 is a critical mediator of intrinsic apoptosis pathway 
and possesses a central nucleotide binding domain called NB-ARC that is also belongs to the 
AAA+ ATPase super family. Upon binding its cognate ligand cytochrome C, Apaf-1 rapidly 
hydrolyze its bound (d)ATP. This process results in a conformational change that eventually 
leads to the formation of heptomeric structure named Apoptosome. Apoptomsome recruits 
and activates caspase-9, a key caspase in mediating intrinsic apoptosis pathway. Largely 
analogous to this process, a group of activated NLR protein also has been shown to 
oligomerize into a large molecular complex termed ‘inflammasome’, and we have shown that 
nucleotide binding/ hydrolysis is important in mediating this oligomerization process ((118) 
and chapter 2). 
The difficulties in the generation and purification of recombinant NLR severely 
impeded the structural study of NLR protein. However, the newly identified Apaf-1 crystal 
structure has provided us a suitable template to perform molecular modeling of the NBD 
domain of NLR. The NBD-ARC domain of Apaf-1 contains an ATP binding α/β fold 
followed by three distinct helices domains. Based on the sequence similarity between Apaf-1 
and NLRs, the NBD domain of NLR has also been bioinfomatically divided into a NATCH 
domain and three NAD domains, which correspond to the respective NBD domains in Apaf-
1 (120). Additionally, there are nine to twelve evolutionary conserved motifs encoded by the 
exon that contains the NBD (6, 102). In the previous chapter, we studied the function of 
Walker A and Walker B, however the function of the remaining sequence motifs remain 
largely elusive. In this report, we sought to use NLR protein Monarch-1 as an example to 
elucidate the biological significance of its conserved motifs. This study provides us insight 
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regarding the structure-function relationship of NLR NBD domain and facilitates the 
understanding of biochemical mechanism of NBD domain function.  
3.2 Materials and methods 
3.2.1 Multiple sequence alignment of NLR NBD domains 
The protein sequences of selected NLR proteins were obtained from Genebank using 
the following accesion number: CIAS1,NP_00488; Monarch-1, NP_653288; CIITA, 
NP_000237; NALP1, NP_127497; NALP2,NP_060322; NALP6, NP612202; NALP7, 
NP_996611; NOD1, NP_006083; NOD2, NP_071445; The alignment was preformed by 
using the Align module of the Vector NTI 10 (Invitrogen) software that is based on the 
CLUSTAL W multiple sequence alignment algorithm. The alignment of NBD domain of 
selected NLR proteins were further manually edited by GeneDoc (ver 2.6.003). 
3.2.2 Cell lines and reagents 
The TLR2 agonist , the synthetic lipoprotein S-[2,3-bis-(palmitoyloxy)-2(2-RS)-
propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH trihydrochloride (Pam3Cys4) was obtained 
from Invivogen. CD40L was obtained from PeproTech. THP-1 cell lines shRNA targeting 
Monarch-1 (THP-shMon) have been described (92, 93).  
3.2.3 Generation of Monarch-1 NBD mutants 
To generate Monarch-1 NBD mutants, a retroviral vector pHSPG (kindly provided by 
Dr. Lishan Su, University of North Carolina) encoding an HA-tagged Monarch-1 was 
subjected to site-directed mutagenesis by Quick-change site-directed mutagenesis kit 
(Strategene). The mutated motifs and its amino acid sequences are shown in Figure 3-1. The 
mutagenesis primers for each motifs are: Motif 1, Forward: CGC GGC AGG GAT AGC 
CGC CGC CAT GCT GGC ACA C; Reverse:GTG TGC CAG CAT GGC GGC GGC TAT 
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CCC TGC CGC G; Motif 2, Forward:CTC TTC TAC ATC AAC GCC GCC GCC ATG 
AAC CAG AGT G; Reverse:CAC TCT GGT TCA TGG CGG CGG CGT TGA TGT AGA 
AGA G; Motif 3: Forward:CTT TTC ATC ATC GCC GGC TTC GCT GCC CTC AAG 
CCT TCT; Reverse: AGA AGG CTT GAG GGC AGC GAA GCC GGC GAT GAT GAA 
AAG; Motif 4: CTA TCT TTG CTC ATC GCC GCA GCC CCC ACG GCT TTG G; 
Reverse: CCA AAG CCG TGG GGG CTG CGG CGA TGA GCA AAG ATA G; Motif 5, 
Forward:GGA GAT CCT GGG CGC CGC TGC CGC AGA AAG GAA GG; Reverse: CCT 
TCC TTT CTG CGG CAG CGG CGC CCA GGA TCT CC; Motif 6, Forward:  CTT CAC 
CAT GTG CGC CGC AGC CCT GGT GTG CTG G; Reverse: CCA GCA CAC CAG GGC 
TGC GGC GCA CAT GGT GAA G; Motif 7, Forward: CAG ACG TCC AGG GCC GCC 
GCT GCA GTG TAC ATG; Reverse: CAT GTA CAC TGC AGC GGC GGC CCT GGA 
CGT CTG; Motif 8, Foward: GGG TTG TGC TCC TTG GGG CTC TGG AAT CAG; 
Reverse: CTG ATT CCA GAG CCC CAA GGA GCA CAA CCC; Motif 9, Forward: CAT 
CCA CTT GAG TGC CGC CGC ATT CTT TGC AGC TAT G; Reverse: CAT AGC TGC 
AAA GAA TGC GGC GGC ACT CAA GTG GAT G; PCR reactions were preformed by 
using PFUturbo DNA polymerase (Stratagene). The PCR products were digested by DpnI for 
1 hour and transformed into XL1-blue supercompetent cells (Stratagene). All mutants were 
confirmed by DNA sequencing. 
3.2.4 Generation of retrovirus 
The retroviral vectors encoding WT and mutants HA-Monarch-1 were cotransfected 
with pVSV-G and pGag-Pol into HEK293T cells by CaPO4 precipitation. Forty eight hours 
after transfection, the virus containing supernatants were harvested and concentrated by 
ultracentrifugation (20,000 rpm, sorvall 5Ti) for 3 hours at 4 °C. The virus pellet were 
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resuspended in culture medium RPMI1640 plus 10% FBS and stored at -80°C. Retrovirus 
stock was titrated by FACS analysis based on the GFP (Green fluorescence protein) 
expression upon infection of HEK293T cells. The titer of concentrated retrovirus was 
typically at 1x107/pfu. 
3.2.5 Infection of THP-1 by retrovirus.  
Human monocytic THP-1 cell line (ATCC TIB-202) were cultured in RPMI 1640 
supplemented by 10% fetal calf serum, 2 mM L-glutamine,1mM sodium pyruvate, 0.1mM 
nonessential amino acids, and streptomycin-penicillin and were grown at 37 °C  with 5% 
CO2. THP-1 plated in 6-well culture plate (5x105 cells/well) were infected with 100 μl 
retroviral supernatant (MOI=2) and 8 μg/ml polybrene (Sigma). Seventy-two hours post 
infection, the GFP positive cells were FACS (Fluorescent-activated cell sorting) (MolFlow, 
Dako cytomation) sorted and further expanded. The purity of retroviral infected THP-1 cells 
was evaluated by GFP expression by FACS analysis (FACS Calibur, Beckman Dickson). 
3.2.6 Western blot 
THP-1 cells were lysed in 50mM Tris.HCl (PH7.6), 150mM NaCl, 2mM EDTA, 1x 
Compelete protease inhibitor cocktail (Roche). The lysate were separated on 4-12% gradient 
mini polyacrylamide gel (Invitrogen) and blot on nitrocelluse membrane. The HA-tagged 
Monarch-1 were blotted with Anti-HA HRP (12CA5) (Roche) and visualized by pico 
Western blot substrates (Pierce). 
3.2.7 ELISA 
Human chemokine BLC, GCP-2 and cytokine IL-6 ELISA (R&D systems) were 
preformed according to the manufacture’s procedure. 
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3.3 Results 
3.3.1 Multiple alignment of NLR NBD domain 
Based on the recently elucidated crystal structure of WD40 truncated Apaf-1, the 
NBD-ARC domain of Apaf-1 contains four subdomain structures: α/β sandwich fold, Helix I 
domain, Winged Helix domain and Helix II domain. Based on the sequence similarity, the 
NBD or the previous NATCH domain of NLR proteins is further divided into four 
subdomains: NATCH, NAD1, NAD2, NAD3 that are correspond to the Apaf-1 subdomains 
respectively. To identify the conserved motifs within the NLR domain and to map those 
conserved motifs on the newly designated subdomain structure, we preformed a multiple 
sequence alignment of 9 selected NLR family proteins. Of these selected proteins, nine 
proteins belong to previously named NALP family that contains N-terminal pyrin domain, 
currently renamed NLRP. Those proteins were CIAS1, NLRP12, NARP1, 2, 6, and 7. The 
other four proteins carry either the N-terminal CARD domain (NOD1, NOD2) or 
Transcriptional activator (CIITA). As shown in Figure 3-1, at least nine conserved motifs are 
found in the NBD domain of NLR. In those nine conserved motifs, five motifs are mapped in 
the NACHT domain that is predicted to adopt the α/β sandwich fold. The first domain is well 
characterized Walker A motif that has a extremely conserved sequence: GxxGxGK[S/T]. The 
lysine residue of Walker A is shown to coordinate the β and γ-phosphate moiety of ATP. The 
third domain is the Walker B motifs that contains a conserved sequence: hhhhhhDxx[D/E]. 
The first aspartic acid  residue typically coordinate the Mg2+ and the second aspartic acid or 
glutamate acid plays an important role in facilitate ATP hydrolysis. Interestingly, CIAS1 
disease associated mutant, D303N maps to the second aspartic acid implying the ATP 
hydrolysis may plays an important role in CIAS1 associated disease pathogenesis. The 
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biochemical functions of Motifs 2, 4, 5 are not well understood. However, several disease-
associated mutants are mapped in these conserved areas. For example, disease-associated 
CIAS1 mutant R260W and NOD2 disease associated mutant R334W/Q are both located in 
the Arginine residue of Motif 2 indicating this region is critical for the function of these 
proteins. The NAD1 subdomain consists of two motifs and the NAD2 domain contains the 
rest of two motifs. We did not find significantly sequence homology within the NAD3 
domain. 
3.3.2 Generation of mutants for conserved motifs in Monarch-1 NBD 
domain 
To further gain insight of the biological functions of NBD motifs, we used NLR 
protein Monarch-1 to test the function of NBD motifs. Previously, we have shown that 
Monarch-1 functions as a negative regulator in both canonical and non-canonical NF-κB 
signaling pathways. Furthermore, we also revealed that purified recombinant Monarch-1 
binds and hydrolyzes ATP while protein bearing mutations in both Walker A and Walker B 
failed to bind ATP. The binding of ATP is critical for the negative regulator function of 
Monarh-1 as the Walker A and B double mutant functions as a dominant negative mutant. In 
this report, we sought to further characterize the biological functions of other conserved 
motifs in the Monarch-1 NBD domain. We introduced triple alanine substitution to the key 
residues of Monarch-1 NBD motifs shown in Figure 3-1. We then generated retrovirus 
encoding the corresponding mutants and infected human THP-1 monocytic cell line. The 
initial infection resulted in approximately 10-30% GFP positive THP-1 cells (Data not 
shown). We then employed the FACS sorting to further purify the GFP+ THP-1 cells from 
GFP negative non-infected parental cell lines. After the expansion of sorted GFP positive 
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cells, we examined the GFP expression. As shown in Figure 3-2A, All 10 cell lines tested 
contains >98 % GFP positive cells, thus indicating our procedure generated a near 
homogenous populations that express wild type or mutant Monarch-1. THP-1 cell lines 
containing Monarch-1 mutant were further expanded and they did not show apparent changes 
in morphology and growth rate (data not shown). To evaluate the expression of wild type and 
mutant Monarch-1 in the THP-1 cells, we used western blot analysis to visualize the HA-
tagged Monarch-1. As shown in Figure 3-2B, all wild type and mutants were successfully 
expressed in the stable THP-1 line. 
3.3.3 The biological function of Motifs in the NBD domain of Monarch-1 
To investigate the biological function of the mutants, we tested the production of 
cytokine IL-6, chemokines GCP-2 and BLC from both wild type and mutant Monarch-1 
expressing THP-1 cells line upon TLR2 and CD40ligand stimulation. We have previously 
shown that Monarch-1 inhibits the non-canonical NF-κB pathway by affecting NIK stability. 
The negative effect of Monarch-1 results in the decreased secretion of IL-6, GCP-1 and BLC 
upon the activation of NF-κB pathway. In the current study, the wild type and all NBD 
mutant of Monarch-1 were stimulated with TLR2 agonist Pam3Cys4 and CD40L, 48 hour 
later, the culture supernatant were assayed for the cytokine and chemokines as indicated 
above. We found that over-expression of Monarch-1 wild type resulted in the reduction of 
IL-6, GCP-1 and BLC. Reducing endogenous Monarch-1 by shRNA mediated gene ablation 
led to a marked increased of assayed cytokine and chemokines (Figure 3-3). This result 
confirms the negative regulator function of Monarch-1. 
A testing of the Monarch-1 NBD mutants show that overexpression of Mutant 1 
(walker A), 3(Walker B), 6 and 9 resulted a significant increase of IL-6, GCP-1, and BLC 
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secretion to a extent that was comparable to that of shRNA expression THP-1(Figure 3-3). 
This result indicates that the mutation of Walker A, Walker B, motif 6, motif 9 not only 
resulted in a non-functional Monarch-1 but also dominant negative Monarch-1 mutants that 
interfere with the function of endogenous wild type Monarch-1. Furthermore, the critical 
roles of NBD motif 6 and 9 for mediating NLR function have not been recognized previously. 
Taken together, We identified that Walker A (motif 1), Walker B(motif 2), Motif 6 and Motif 
9 are critical function structures in the Monarch-1 NBD domain. 
3.4 Discussion 
In this report, we examined the biological function of nine conserved motifs in the 
NBD domain of NLR protein Monarch-1. Our previous report indicated that overexpression 
of Walker A and Walker B double mutant leads to a dominant negative mutant phenotype. In 
this study, the Walker A or Walker B single mutant was revealed to behave similarly to the 
Walker and Walker B double mutant. This results implies that severe disruption of either 
Walker A or Walker B by triple alanine substitution is likely sufficient for the disruption of 
nucleotide binding. This result was in line with a previous report showing that triple alanine 
substitution of either Walker A or Walker B motif within the context of the CIAS1/cryopyrin 
gain-of-function mutants completely abolished the gain-of-function phenotype associated 
with autoinflammatory diseases. This result also agrees with the finding from a random 
mutagenesis based study on NOD2 protein, in which the Walker B mutant D379A (the first 
aspartic acid in Walker B motif) result a loss-of function phenotype (126). Taken together, 
these results conclusively demonstrated the requirement of ATP binding in NLR function. 
One caveat of current study is the alanine substitution of Walker A and Walker B mutant did 
not separates the ATP hydrolysis function from ATP binding. It is of interest to generate a 
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Monarch-1 mutant that retains ATP binding but losses ATP hydrolysis activity (creating an 
ATP trap). Such mutant will enable us evaluate the role of ATP hydrolysis in NLR function. 
It has been shown that the main function of the second aspartic acid of Walker B motif is to 
attack the water molecular but not ATP binding per Se.  By selectively mutating this residue, 
we might create a NLR protein that retains ATP binding but losses ATP hydrolysis activity. 
In addition to the Walker A and Walker B, we further revealed that the Motif 6 and 9 
is critical for Monarch-1 function. However, the biochemical functions of those motifs are 
largely unknown. According to a molecular modeling study, the NAD1 and NAD2 are likely 
folded back on the nucleotide binding core structure (116). It is highly likely that the key 
residues of NAD1 and NAD 2 domain motifs indirectly contact with bound ATP molecule, 
therefore stabilize or facilitate the ATP binding/hydrolysis. To test this possibility, the 
nucleotide binding activities of these mutants have to be measured in vitro. Another 
possibility is that NAD1 and NAD2 domains have no impact in nucleotide binding, but 
facilitate or mediate the ATP driven conformation change. The proof of this hypothesis 
awaits the detailed structural study due to negative functional nature of Monarch-1, our 
experiment design only selects the dominant negative mutants. The recessive mutant and 
gain-of-function mutant likely evade our screen strategy. Therefore, further study in 
evaluating the NBD conserved motifs shall be perform using NLRs such as NLRP3/CIAS1 
whereas a positive effect can be easily monitored. 
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Figure 3-1The NLR NBD domain structure and multiple sequence alignment. 
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Figure 3-1. The NLR NBD domain structure and multiple sequence alignment.  The 
homology of NBD domain of selected NLR proteins were aligned using CLUSTAL W 
multiple sequence alignment algorism. The black boxes indicate identical residues, the three 
levels of grey box , which range from dark grey to light grey, depicts residues with most 
similarity to residues with less similarity. Numbers to the right of the sequences indicate the 
positions of the last residue shown. Amino acids are showed in the single-letter (code). Text 
labels denote the function of key residues within the motifs and disease associated mutants. 
The position of key residues that were mutated to alaine in the Monarch-1 protein are also 
denoted. The distribution of nine motifs in the Nucleotide binding domain of NLR is 
depicted in the domains structure diagram. CIAS, cold-induced autoinflammatory 
syndrome;CINCA, chronic infantile neurologic cutaneous articular; MWS, Muckle-wells 
syndrome;FCAS, familia cold autoinflammatory syndrome.
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Figure 3-2 Generation of THP-1 cells expressing Monarch-1 wild type and mutants. 
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Figure 3-2  Generation of THP-1 cells expressing wild type and Monarch-1NBD mutants. 
THP-1 cells were infected by retrovirus encoding wild type and NBD mutants. 3 days post 
infection, the GFP positive cells were FACS sorted and further expanded. A. the GFP 
expression of wild type and Monarch-1 NBD mutants stably expressing cells lines. B. 
Western blot analysis of  THP-1 expressing wild type and NBD mutant Monarch-1 using 
anti-HA antibody. 
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Figure 3-3 Motifs 1, 3, 6, 9 are required for Monarch-1 mediated suppression of proinflammatory 
cytokine and chemokine production.  
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Figure 3-3  THP-1 cells expressing empty vector (Mock), full length WT Monarch-1 (WT), 
full length Monarch-1 NBD mutants (Motif 1-9 were assigned as M1-9) and THP-1 shRNA 
Monacrch-1 Knock-down cells were stimulated with 200ng/ml Pam3Cys4 for 18 h and then 
250 ng/ml CD40L for an additional 5 h.  Cell culture supernatants were harvested and 
cytokine/chemokine levels determined by ELISA. 
Chapter 4 Conclusions and future directions
      The newly discovered NLR/CATERPILLER gene family has emerged as a key 
set of genes that plays a vital role in mediating the innate immune response. By the 
combination of traditional molecular biology, biochemical and genetic tools such as DNA 
microarray, yeast two-hybrid, co-immunopricipitation, gene knockout as well as newly 
emerged experimental methods including proteomics, siRNA or shRNA based gene 
ablation, great strides have been made in the last several years in understanding the 
biological functions of NLR proteins. NLR proteins functions as intracellular bacteria 
sensor to detect the invading pathogen derived products and to activate a number of 
proinflammatory signaling pathways including NF-κB signaling pathway. A group of 
NLRs responds to pathogen-derived products or -induced perturbations and activates 
caspase-1 leading to the secretion of IL-1β. In addition, NLRs also elicits a rapid cell death 
program manifested as either apoptosis or necrosis. Finally, several NLRs have been 
shown to act as negative regulators of inflammatory response by dampening the 
proinflammatory cytokines and chemokine releases. 
       The defining feature of NLR protein is the central localized nucleotide binding 
domain that is extremely conserved through the evolution. The nucleotide binding of NLR 
proteins is thought to play a key role in their oligomerization and complex formation . 
However, until the start of this thesis study, definitive evidence for the nucleotide binding 
capacity of NLR protein has not been shown. The biological role of nucleotide binding 
also remained elusive. This thesis study aims to characterize the biochemical property of 
nucleotide binding by the NLR protein, Monarch-1, and to examine the role of nucleotide 
binding in Monarch-1 function. The results from this study along with a study from a 
colleague in the lab, demonstrate the nucleotide binding activity of NLR proteins 
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(Monarch-1 and Cryopyrin).  These studies show the critical roles of nucleotide binding in 
regulating the function of NLR proteins. 
      The daunting difficulties in the generation and purification of NLR protein 
impede the biochemical and structural study of NLR protein for years. The complex 
domain structure and pro-oligomerization nature of NLR protein often render the protein 
insoluble during the generation of recombinant proteins. Through the course of the study, 
several methods suitable for the generation and purification of NLR proteins have been 
successfully developed. The MBP fusion protein approach coupled with dual affinity 
purification strategy is robust and reliable to generate large amount of NLR NBD fusion 
proteins for the study of nucleotide binding property. The caveat of this approach is that 
the size restriction of MBP fusion partner precludes the study of full length protein. On the 
other hand, the episomal based mammalian systems (293EBNA) system generates longer 
protein product but less quantity than that of the MBP fusion protein systems. Although the 
tour de force effort has been made to generate and purify the full-length Monarch-1, the 
result is still disappointing due to the insolubility and cytotoxicity issues. Future studies 
shall explore novel methods and purification strategies to overcome these challenging 
problems. Alternatively, we shall not abandon the traditional biochemical purification 
strategies that aim to purify endogenous protein/complex. With current technological 
advances in large-scale mammalian cell culture, it is feasible to obtain 10-50 liters of 
mammalian cell culture (i.e. THP-1 cells).  Thus, the purification of NLR protein/complex 
by traditional biochemical strategy is in the foreseeable future. 
      In this thesis study, solid evidence demonstrating the nucleotide binding 
property of NLR protein has been provided. However, several remaining issues still need 
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to be further addressed in future studies. First, we do not have evidence to demonstrate the 
prebound status of nucleotide in NLR proteins. Insect cell-derived Apaf-1 is prebound by 
dATP. It is of interest to examine if this is the case for the NLR proteins. Solving this issue 
needs a large amount of protein and a sensitive assay such as mass spectrometry  to detect 
the trace amount of  prebound nucleotide. Second, the ATPase properties and ATP 
hydrolysis cycle of NLR protein needs to be fully characterized. The basic enzyme 
properties such as Vmax and Km needs to be measured. Third, the nucleotide binding 
activity and the role of nucleotide binding of the NLR protein complex in lieu of a single 
NLR protein awaits to be examine in in vitro reconstituted protein complex. Finally, even 
though large amount of full length NLR proteins is difficult to obtain, it is still feasible to 
determine the subdomain structure of NLR protein. The structural study will provide us 
invaluable knowledge in understanding the structure-function relationship of NLR protein. 
      Current study examined the biological role of nucleotide binding in NLR 
function by over-expressing NLR wild type or mutant protein in cell lines. The caveat of 
this strategy is that the amount of expressed protein often largely exceeds the endogenous 
protein, thus this artificial condition may not recapitulate physiological conditions. One 
approach to overcome these drawbacks is to generate BAC transgenic mice bearing the 
NLR nucleotide binding mutant and /or disease-associate mutants. In light of the current 
progress of BAC recombineering and BAC transgenic technology (127-130), the 
generation of BAC transgenic is rapid and efficient. The large size of BAC clone retains all 
the transcription/epigenetic control elements that allow faithful expression of target protein 
with precise temporal and spatial control. The BAC recombineering technology also 
allows extensive manipulation of target sequence. For example, we could built IRES 
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(internal ribosome entry site)-GFP in 3’ UTR region of NLR protein to trace the NLR 
protein in vivo. We can tagged targeted NLR protein with small peptide tag to facilitate the 
detection of transgene. We also could generate point mutations that resemble the disease 
associated SNP in NLR protein. Furthermore, the BAC transgenic mice could subsequently 
be intercrossed with NLR gene deficient mice to obtain more physiological- relevant 
experimental condition. The BAC transgenic mice are powerful tools especially for 
examining the function of NLR protein cryopyrin, whereas its disease associated mutants 
are dominant gain-of-function mutants. 
      The current thesis work establishes the nucleotide binding as a major 
biochemical and biological property of NLR protein. The findings of this work not only 
establish the foundation for future detailed biochemical studies, but also provide us with 
the possible means for pharmacological intervention of NLR functions. 
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